Katherine Barnett Peters

Katherine Barnett Peters
Associate Professor of Neurosurgery

Dr. Katy Peters, MD Ph.D. FAAN is an associate professor of neurology and neurosurgery at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. Her academic medical career started at Stanford University School of Medicine, receiving an MD and Ph.D. in Cancer Biology. After completing a neurology residency at Johns Hopkins University and a fellowship in cognitive neurosciences, Katy joined the PRTBTC as a neuro-oncology fellow. In 2009, she became a faculty member at PRTBTC. With a fantastic team of nursing and advanced practice providers, she actively sees and cares for patients with primary brain tumors. Her research interests include supportive care for brain cancer patients, cognitive dysfunction in cancer patients, and physical function and activity of brain cancer patients. While she runs clinical trials to treat primary brain tumors, her key interest is on clinical trials that focus on improving brain tumor patients' quality of life and cognition. In 2019, the PRTBTC designated her as the Director of Supportive Care, thus furthering the PRTBTC and her committee to better the quality of life for brain tumor patients. She is active in teaching medical school students, residents, fellows, and advanced practice providers and is the Program Director of the PRTBRC neuro-oncology fellowship. She is board certified by the American Board of Psychiatry and Neurology and the United Council of Neurologic Subspecialties for neuro-oncology.

Current Research Interests

My research interest involve the supportive care of patients with brain tumors. I am particularly interested in the quality of life in patients with brain tumors by improving fatigue, protecting cognition, and improving physical function. Additionally, I serve at the principal investigator for treatment trials for primary brain tumors with a particular interest in low grade glioma, IDH mutant tumors, and primary CNS lymphoma. I am the Director of Supportive Care at the Preston Robert Tisch Brain Tumor Center at Duke.

Office Hours

Per Request

Current Appointments & Affiliations

Associate Professor of Neurosurgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2020
Vice Chair for Education in the Department of Neurology, Neurology, Clinical Science Departments 2022
Associate Professor in Neurology, Neurology, Clinical Science Departments 2017
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2013

Contact Information

047 Baker House, Trent Drive, Box 3624, Durham, NC 27710
katherine.peters@duke.edu (919) 684-6173

Background
Education, Training, & Certifications
- Fellow in Neuro-Oncology, Surgery, Duke University 2008 - 2009
- Resident and Fellow in Neurology, Neurology, Johns Hopkins University 2004 - 2008
- Intern, Medicine, Johns Hopkins University 2003 - 2004
- M.D., Stanford University 2003
- Ph.D., Stanford University 2003
Medical Licensure
- 2009-00404. North Carolina. 2009
Previous Appointments & Affiliations
- Associate Professor of Neurosurgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2017 - 2020
- Associate Professor in Neurosurgery, Neurosurgery, Neurosurgery 2016 - 2017
- Associate Professor of Neurology, Neurology, General & Community Neurology, Neurology 2016 - 2017
- Assistant Professor in Surgery, Neurosurgery, Neurosurgery 2011 - 2016
- Assistant Professor of Neurology, Neurology, General & Community Neurology, Neurology 2013 - 2016
- Medical Instructor in the Department of Medicine, Neurology, Clinical Science Departments 2009 - 2013
- Medical Instructor in the Department of Surgery, Neurosurgery, Neurosurgery 2009 - 2011
- Instructor, Temporary in the Department of Medicine, Neurology, Clinical Science Departments 2009
Leadership & Clinical Positions at Duke
- Program Director, Neuro-Oncology Fellowship
  Director of Supportive Care, The Preston Robert Tisch Brain Tumor Center at Duke
  Vice-Chair of Education, Department of Neurology
Recognition
In the News
- FEB 16, 2022 AARP Magazine
  
  6 Brain Tumor Symptoms You Should Not Ignore
- AUG 1, 2021 Brain&Life
  
  How Patients with Terminal Illnesses Get Access To Experimental Drugs
- OCT 1, 2020 Brain&Life
  
  How to Ease Social Isolation During the Pandemic
- JAN 11, 2018 Women's Health Magazine
  
  Would You Be Able to Recognize These 4 Brain Tumor Symptoms?
- APR 25, 2014 The News & Observer
  
  Apex cancer patient continues his marathon beyond Boston finish line
Awards & Honors
Expertise
Subject Headings
Global Scholarship
- Expertise
  - United States of America (Country)
Research
Selected Grants
External Relationships
- BioMimetix JVLLC
- Eisai
- Novocure
- Nuvox Pharmaceutical
- Ono pharma USA, Inc.
- Sapience
- Servier
- Varian Medical Systems
- Vivacitas Oncology
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Hanzlik, Emily, Bridget Archambault, Mays El-Dairi, Kristin Schroeder, Mallika P. Patel, Eric S. Lipp, Katherine B. Peters, David M. Ashley, and Daniel Landi. “Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors.” J Pediatr Hematol Oncol 45, no. 4 (May 1, 2023): e464–70. https://doi.org/10.1097/MPH.0000000000002598.
    Full Text Link to Item
  - Vaios, Eugene J., Sebastian F. Winter, Helen A. Shih, Jorg Dietrich, Katherine B. Peters, Scott R. Floyd, John P. Kirkpatrick, and Zachary J. Reitman. “Novel Mechanisms and Future Opportunities for the Management of Radiation Necrosis in Patients Treated for Brain Metastases in the Era of Immunotherapy.” Cancers (Basel) 15, no. 9 (April 24, 2023). https://doi.org/10.3390/cancers15092432.
    Full Text Link to Item
  - Vaios, Eugene J., Kristen A. Batich, Anne F. Buckley, Anastasie Dunn-Pirio, Mallika P. Patel, John P. Kirkpatrick, Ranjit Goudar, and Katherine B. Peters. “Addendum: Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma.” Oncotarget 13 (October 20, 2022): 1165. https://doi.org/10.18632/oncotarget.28292.
    Full Text Link to Item
  - Yao, Xiaoliang, Dayun Yan, Li Lin, Jonathan H. Sherman, Katherine B. Peters, Stephen T. Keir, and Michael Keidar. “Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide.” Acs Appl Bio Mater 5, no. 4 (April 18, 2022): 1610–23. https://doi.org/10.1021/acsabm.2c00018.
    Full Text Link to Item
  - Peters, Katherine B., Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E. Herndon, Elizabeth S. Miller, et al. “Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.” Support Care Cancer 30, no. 4 (April 2022): 3463–71. https://doi.org/10.1007/s00520-021-06738-0.
    Full Text Link to Item
  - Au, Trang H., Connor Willis, Maija Reblin, Katherine B. Peters, Phioanh Leia Nghiemphu, Jennie W. Taylor, Howard Colman, et al. “Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.” Support Care Cancer 30, no. 2 (February 2022): 1365–75. https://doi.org/10.1007/s00520-021-06514-0.
    Full Text Link to Item
  - Au, Trang H., Connor Willis, Maija Reblin, Katherine B. Peters, Phioanh Leia Nghiemphu, Jennie W. Taylor, Howard Colman, et al. “Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.” Support Care Cancer 30, no. 2 (February 2022): 1377–78. https://doi.org/10.1007/s00520-021-06691-y.
    Full Text Link to Item
  - Patel, Mallika P., Eric S. Lipp, Elizabeth S. Miller, Patrick N. Healy, James E. Herndon, and Katherine B. Peters. “Availability and role of clinical pharmacists in ambulatory neuro-oncology.” Neurooncol Pract 9, no. 1 (February 2022): 18–23. https://doi.org/10.1093/nop/npab060.
    Full Text Link to Item
  - Halasz, Lia M., Albert Attia, Lisa Bradfield, Daniel J. Brat, John P. Kirkpatrick, Nadia N. Laack, Nafisha Lalani, et al. “Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.” Pract Radiat Oncol 12, no. 5 (2022): 370–86. https://doi.org/10.1016/j.prro.2022.05.004.
    Full Text Link to Item
  - Kent, Collin L., Yvonne M. Mowery, Olayode Babatunde, Ato O. Wright, Ian Barak, Frances McSherry, James E. Herndon, et al. “Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.” Adv Radiat Oncol 7, no. 3 (2022): 100878. https://doi.org/10.1016/j.adro.2021.100878.
    Full Text Link to Item
  - Low, Justin T., John P. Kirkpatrick, and Katherine B. Peters. “Pineal Parenchymal Tumors of Intermediate Differentiation Treated With Ventricular Radiation and Temozolomide.” Adv Radiat Oncol 7, no. 1 (2022): 100814. https://doi.org/10.1016/j.adro.2021.100814.
    Full Text Link to Item
  - Peters, Katherine B. “Targeting BRAF-mutant glioma: reflections on the ROAR trial.” Lancet Oncol 23, no. 1 (January 2022): 3–4. https://doi.org/10.1016/S1470-2045(21)00662-8.
    Full Text Link to Item
  - Vaios, Eugene J., Kristen A. Batich, Anne F. Buckley, Anastasie Dunn-Pirio, Mallika P. Patel, John P. Kirkpatrick, Ranjit Goudar, and Katherine B. Peters. “Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma.” Oncotarget 13 (2022): 576–82. https://doi.org/10.18632/oncotarget.28222.
    Full Text Link to Item
  - M Lewis-Gonzalez, Jessica, Mallika P Patel, and Katherine B Peters. “Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient.” Cns Oncol 10, no. 4 (December 1, 2021): CNS78. https://doi.org/10.2217/cns-2021-0006.
    Full Text Link to Item
  - Kang, Jennifer H., Meghan Price, Tara Dalton, Luis Ramirez, Peter E. Fecci, Arif H. Kamal, Margaret O. Johnson, Katherine B. Peters, and Courtney R. Goodwin. “Palliative Care Use for Critically Ill Patients With Brain Metastases.” J Pain Symptom Manage 62, no. 5 (November 2021): 927–35. https://doi.org/10.1016/j.jpainsymman.2021.05.003.
    Full Text Link to Item
  - Kang, Jennifer H., Christa B. Swisher, Evan D. Buckley, James E. Herndon, Eric S. Lipp, John P. Kirkpatrick, Annick Desjardins, et al. “Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.” Cns Oncol 10, no. 3 (September 1, 2021): CNS77. https://doi.org/10.2217/cns-2021-0009.
    Full Text Open Access Copy Link to Item
  - Mellinghoff, Ingo K., Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, et al. “Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.” Clin Cancer Res 27, no. 16 (August 15, 2021): 4491–99. https://doi.org/10.1158/1078-0432.CCR-21-0611.
    Full Text Link to Item
  - Mayo, Samantha J., Maryam Lustberg, Haryana M Dhillon, Zev M. Nakamura, Deborah H. Allen, Diane Von Ah, Michelle C Janelsins, et al. “Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.” Support Care Cancer 29, no. 6 (June 2021): 2821–40. https://doi.org/10.1007/s00520-020-05860-9.
    Full Text Link to Item
  - Low, Justin Thomas, Shih-Hsiu Wang, and Katherine B Peters. “Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.” Cns Oncol 10, no. 2 (June 1, 2021): CNS71. https://doi.org/10.2217/cns-2020-0030.
    Full Text Link to Item
  - Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Elizabeth S. Miller, Sarah Woodring, et al. “Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.” Neurooncol Pract 8, no. 3 (June 2021): 299–309. https://doi.org/10.1093/nop/npaa084.
    Full Text Link to Item
  - Kumthekar, Priya, Erin M. Dunbar, Katherine B. Peters, Priscilla K. Brastianos, and Alyx B. Porter. “A broad perspective on evaluating bias in the neuro-oncology workplace.” Neuro Oncol 23, no. 3 (March 25, 2021): 498–99. https://doi.org/10.1093/neuonc/noaa286.
    Full Text Link to Item
  - Taylor, Breanna, Mallika P. Patel, and Katherine B. Peters. “When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.” Cns Oncol 10, no. 1 (March 1, 2021): CNS69. https://doi.org/10.2217/cns-2020-0028.
    Full Text Link to Item
  - Nayak, Lakshmi, Annette M. Molinaro, Katherine Peters, Jennifer L. Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, et al. “Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.” Clin Cancer Res 27, no. 4 (February 15, 2021): 1048–57. https://doi.org/10.1158/1078-0432.CCR-20-2500.
    Full Text Link to Item
  - Thakkar, Jigisha P., Vikram C. Prabhu, Katherine B. Peters, and Rimas V. Lukas. “What is New in Neuro-oncology?” Neurol Clin 39, no. 1 (February 2021): 163–79. https://doi.org/10.1016/j.ncl.2020.09.009.
    Full Text Link to Item
  - Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.” Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.
    Full Text Open Access Copy Link to Item
  - Lee, Jessica W., John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina M. Randazzo, et al. “Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.” Front Oncol 11 (2021): 631618. https://doi.org/10.3389/fonc.2021.631618.
    Full Text Open Access Copy Link to Item
  - Mrugala, Maciej M., Quinn T. Ostrom, Shelley M. Pressley, Jennie W. Taylor, Alissa A. Thomas, Jeffrey S. Wefel, Scott L. Coven, et al. “The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment.” Neurooncol Adv 3, no. 1 (2021): vdab035. https://doi.org/10.1093/noajnl/vdab035.
    Full Text Link to Item
  - Adil, Syed M., Sarah E. Hodges, Ryan M. Edwards, Lefko T. Charalambous, Zidanyue Yang, Musa Kiyani, Alexis Musick, et al. “Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States.” Neurooncol Pract 7, no. 6 (December 2020): 636–45. https://doi.org/10.1093/nop/npaa041.
    Full Text Link to Item
  - Nabors, Louis Burt, Jana Portnow, Manmeet Ahluwalia, Joachim Baehring, Henry Brem, Steven Brem, Nicholas Butowski, et al. “Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 11 (November 2, 2020): 1537–70. https://doi.org/10.6004/jnccn.2020.0052.
    Full Text Link to Item
  - Schreck, Karisa C., Mallika P. Patel, Jan Wemmer, Stuart A. Grossman, and Katherine B. Peters. “RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events.” Neurooncol Pract 7, no. 4 (July 2020): 369–75. https://doi.org/10.1093/nop/npaa006.
    Full Text Link to Item
  - Brenner, Andrew J., Katherine B. Peters, James Vredenburgh, Felix Bokstein, Deborah T. Blumenthal, Shlomit Yust-Katz, Idit Peretz, et al. “Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.” Neuro Oncol 22, no. 5 (May 15, 2020): 694–704. https://doi.org/10.1093/neuonc/noz231.
    Full Text Link to Item
  - Patel, Mallika P., Sarah Woodring, Dina M. Randazzo, Henry S. Friedman, Annick Desjardins, Patrick Healy, James E. Herndon, et al. “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” Support Care Cancer 28, no. 5 (May 2020): 2229–38. https://doi.org/10.1007/s00520-019-05039-x.
    Full Text Link to Item
  - Patel, Mallika P., John P. Kirkpatrick, Margaret O. Johnson, Patrick Healy, James E. Herndon, Eric S. Lipp, Elizabeth S. Miller, et al. “Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.” J Neurooncol 147, no. 2 (April 2020): 477–83. https://doi.org/10.1007/s11060-020-03446-3.
    Full Text Link to Item
  - T Low, Justin, and Katherine B Peters. “Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.” Cns Oncol 9, no. 1 (March 1, 2020): CNS51. https://doi.org/10.2217/cns-2019-0022.
    Full Text Link to Item
  - Kim, Jung Young, Katherine B. Peters, James E. Herndon, and Mary Lou Affronti. “Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma.” J Adv Pract Oncol 11, no. 7 (2020): 684–92. https://doi.org/10.6004/jadpro.2020.11.7.3.
    Full Text Open Access Copy Link to Item
  - Peters, Katherine B. “Revisiting anti-angiogenic therapy for recurrent glioblastoma.” Transl Cancer Res 8, no. Suppl 6 (December 2019): S569–72. https://doi.org/10.21037/tcr.2019.05.25.
    Full Text Link to Item
  - Johnson, Margaret O., John P. Kirkpatrick, Mallika P. Patel, Annick Desjardins, Dina M. Randazzo, Henry S. Friedman, David M. Ashley, and Katherine B. Peters. “The role of chemotherapy in the treatment of central neurocytoma.” Cns Oncol 8, no. 3 (November 1, 2019): CNS41. https://doi.org/10.2217/cns-2019-0012.
    Full Text Open Access Copy Link to Item
  - Chan, Alexandre, Daniel L. Hertz, Manuel Morales, Elizabeth J. Adams, Sharon Gordon, Chia Jie Tan, Nathan P. Staff, et al. “Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.” Support Care Cancer 27, no. 10 (October 2019): 3729–37. https://doi.org/10.1007/s00520-019-04987-8.
    Full Text Link to Item
  - Kim, Jung-Young, Jennifer G. Jackman, Sarah Woodring, Frances McSherry, James E. Herndon, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Second primary cancers in long-term survivors of glioblastoma.” Neurooncol Pract 6, no. 5 (September 2019): 386–91. https://doi.org/10.1093/nop/npz001.
    Full Text Link to Item
  - Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.” Complement Ther Clin Pract 36 (August 2019): 43–48. https://doi.org/10.1016/j.ctcp.2019.05.002.
    Full Text Link to Item
  - Adekanmbi, Adefisayo, Katherine B. Peters, Evangelia Razis, Augustine A. Adeolu, Rimas V. Lukas, and James A. Balogun. “Neurooncology Research in Nigeria: Great Untapped Potential.” World Neurosurg 124 (April 2019): 381–85. https://doi.org/10.1016/j.wneu.2018.12.192.
    Full Text Link to Item
  - Desjardins, Annick, James E. Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.” Health Sci Rep 2, no. 4 (April 2019): e114. https://doi.org/10.1002/hsr2.114.
    Full Text Link to Item
  - Batich, Kristen A., Richard F. Riedel, John P. Kirkpatrick, Betty C. Tong, William C. Eward, Char Loo Tan, Patricia D. Pittman, Roger E. McLendon, and Katherine B. Peters. “Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread.” Front Oncol 9 (2019): 1322. https://doi.org/10.3389/fonc.2019.01322.
    Full Text Link to Item
  - Shen, Erica, Margaret O. Johnson, Jessica W. Lee, Eric S. Lipp, Dina M. Randazzo, Annick Desjardins, Roger E. McLendon, et al. “Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort.” Neurooncol Adv 1, no. 1 (2019): vdz036. https://doi.org/10.1093/noajnl/vdz036.
    Full Text Link to Item
  - Semmel, Deborah, Courtney Ware, Jung Young Kim, and Katherine B. Peters. “Evidence-based Treatment for Low-grade Glioma.” Semin Oncol Nurs 34, no. 5 (December 2018): 465–71. https://doi.org/10.1016/j.soncn.2018.10.008.
    Full Text Link to Item
  - Affronti, Mary Lou, Dina Randazzo, Eric S. Lipp, Katherine B. Peters, Susan C. Herndon, Sarah Woodring, Patrick Healy, Christina K. Cone, James E. Herndon, and Susan M. Schneider. “Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.” Semin Oncol Nurs 34, no. 5 (December 2018): 472–85. https://doi.org/10.1016/j.soncn.2018.10.006.
    Full Text Link to Item
  - Kang, Jennifer H., Anne F. Buckley, Seema Nagpal, Nancy Fischbein, and Katherine B. Peters. “A Diffuse Leptomeningeal Glioneuronal Tumor Without Diffuse Leptomeningeal Involvement: Detailed Molecular and Clinical Characterization.” J Neuropathol Exp Neurol 77, no. 9 (September 1, 2018): 751–56. https://doi.org/10.1093/jnen/nly053.
    Full Text Link to Item
  - Affronti, Mary Lou, Jennifer Gamboa Jackman, Frances McSherry, James E. Herndon, Elwood C. Massey, Eric Lipp, Annick Desjardins, et al. “Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.” Oncologist 23, no. 8 (August 2018): 889-e98. https://doi.org/10.1634/theoncologist.2018-0149.
    Full Text Link to Item
  - Desjardins, Annick, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, et al. “Recurrent Glioblastoma Treated with Recombinant Poliovirus.” N Engl J Med 379, no. 2 (July 12, 2018): 150–61. https://doi.org/10.1056/NEJMoa1716435.
    Full Text Link to Item
  - Vaslow, Zachary, Katherine Peters, John Kirkpatrick, Frances McSherry, James Herndon, Eric Lipp, Margaret O. Johnson, et al. “Long-term outcomes of adult patients with ependymoma.” Neurology 90, no. 15 (April 10, 2018): P6.150-P6.150.
    Link to Item
  - Peters, Katherine B., Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Annick Desjardins, David A. Reardon, and Henry S. Friedman. “Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.” J Neurooncol 137, no. 2 (April 2018): 349–56. https://doi.org/10.1007/s11060-017-2724-1.
    Full Text Link to Item
  - Dunn-Pirio, Anastasie M., Sarah Woodring, Eric Lipp, James E. Herndon, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Adjunctive perampanel for glioma-associated epilepsy.” Epilepsy Behav Case Rep 10 (2018): 114–17. https://doi.org/10.1016/j.ebcr.2018.09.003.
    Full Text Link to Item
  - Nabors, Louis Burt, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, et al. “NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.” J Natl Compr Canc Netw 15, no. 11 (November 2017): 1331–45. https://doi.org/10.6004/jnccn.2017.0166.
    Full Text Link to Item
  - Young, Jacob S., Steven J. Chmura, Derek A. Wainwright, Bakhtiar Yamini, Katherine B. Peters, and Rimas V. Lukas. “Management of glioblastoma in elderly patients.” J Neurol Sci 380 (September 15, 2017): 250–55. https://doi.org/10.1016/j.jns.2017.07.048.
    Full Text Link to Item
  - Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.” J Neurooncol 134, no. 2 (September 2017): 363–69. https://doi.org/10.1007/s11060-017-2535-4.
    Full Text Link to Item
  - Mazurowski, Maciej A., Kal Clark, Nicholas M. Czarnek, Parisa Shamsesfandabadi, Katherine B. Peters, and Ashirbani Saha. “Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.” J Neurooncol 133, no. 1 (May 2017): 27–35. https://doi.org/10.1007/s11060-017-2420-1.
    Full Text Link to Item
  - Czarnek, Nicholas, Kal Clark, Katherine B. Peters, and Maciej A. Mazurowski. “Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.” J Neurooncol 132, no. 1 (March 2017): 55–62. https://doi.org/10.1007/s11060-016-2359-7.
    Full Text Link to Item
  - Mehta, M., P. Wen, R. Nishikawa, D. Reardon, and K. Peters. “Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.” Crit Rev Oncol Hematol 111 (March 2017): 60–65. https://doi.org/10.1016/j.critrevonc.2017.01.005.
    Full Text Link to Item
  - Affronti, Mary Lou, Sarah Woodring, Katherine B. Peters, James E. Herndon, Frances McSherry, Patrick N. Healy, Annick Desjardins, James J. Vredenburgh, and Henry S. Friedman. “A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.” Ther Clin Risk Manag 13 (2017): 33–40. https://doi.org/10.2147/TCRM.S122480.
    Full Text Link to Item
  - Khagi, S., and K. B. Peters. “Antiangiogenic virotherapy: VB-111 targeting glioma.” Expert Opinion on Orphan Drugs 4, no. 11 (November 1, 2016): 1099–1103. https://doi.org/10.1080/21678707.2016.1235971.
    Full Text
  - Randazzo, Dina, and Katherine B. Peters. “Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.” Cns Oncol 5, no. 4 (October 2016): 241–49. https://doi.org/10.2217/cns-2016-0010.
    Full Text Link to Item
  - Kent, C. L., Y. M. Mowery, A. O. Wright, G. J. Kim, A. Desjardins, K. B. Peters, G. Vlahovic, et al. “Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With Radiation Therapy: A Single-Institution Retrospective Analysis.” Int J Radiat Oncol Biol Phys 96, no. 2S (October 1, 2016): E83–84. https://doi.org/10.1016/j.ijrobp.2016.06.802.
    Full Text Link to Item
  - Mohan, Suyash, Sanjeev Chawla, Sumei Wang, Gaurav Verma, Aaron Skolnik, Steven Brem, Katherine B. Peters, and Harish Poptani. “Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.” Cns Oncol 5, no. 3 (July 2016): 137–44. https://doi.org/10.2217/cns-2016-0003.
    Full Text Link to Item
  - Weitzel, Douglas H., Artak Tovmasyan, Kathleen A. Ashcraft, Alina Boico, Samuel R. Birer, Kingshuk Roy Choudhury, James Herndon, et al. “Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.” Environ Mol Mutagen 57, no. 5 (June 2016): 372–81. https://doi.org/10.1002/em.22021.
    Full Text Link to Item
  - Dunn-Pirio, Anastasie M., Elizabeth Howell, Roger E. McLendon, and Katherine B. Peters. “Single-Agent Carboplatin for a Rare Case of Pilomyxoid Astrocytoma of the Spinal Cord in an Adult with Neurofibromatosis Type 1.” Case Rep Oncol 9, no. 3 (2016): 568–73. https://doi.org/10.1159/000449406.
    Full Text Link to Item
  - Dunn-Pirio, Anastasie M., Santoshi Billakota, and Katherine B. Peters. “Postictal Magnetic Resonance Imaging Changes Masquerading as Brain Tumor Progression: A Case Series.” Case Rep Oncol 9, no. 2 (2016): 358–62. https://doi.org/10.1159/000447350.
    Full Text Link to Item
  - Robertson, Matthew E., Frances McSherry, James E. Herndon, and Katherine B. Peters. “Insomnia and its associations in patients with recurrent glial neoplasms.” Springerplus 5, no. 1 (2016): 823. https://doi.org/10.1186/s40064-016-2578-6.
    Full Text Open Access Copy Link to Item
  - Peters, Katherine B., Emil Lou, Annick Desjardins, David A. Reardon, Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Henry S. Friedman, and James J. Vredenburgh. “Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.” Oncologist 20, no. 7 (July 2015): 727–28. https://doi.org/10.1634/theoncologist.2015-0135.
    Full Text Link to Item
  - Ghiaseddin, Ashley, and Katherine B. Peters. “Use of bevacizumab in recurrent glioblastoma.” Cns Oncol 4, no. 3 (2015): 157–69. https://doi.org/10.2217/cns.15.8.
    Full Text Link to Item
  - Weitzel, Douglas H., Artak Tovmasyan, Kathleen A. Ashcraft, Zrinka Rajic, Tin Weitner, Chunlei Liu, Wei Li, et al. “Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.” Mol Cancer Ther 14, no. 1 (January 2015): 70–79. https://doi.org/10.1158/1535-7163.MCT-14-0343.
    Full Text Link to Item
  - Lopez, Giselle, Roger E. McLendon, and Katherine B. Peters. “Supratentorial tanycytic ependymoma in an adult male: case report and review of literature.” Case Rep Oncol 8, no. 1 (2015): 159–63. https://doi.org/10.1159/000380906.
    Full Text Open Access Copy Link to Item
  - Mazurowski, Maciej A., Jing Zhang, Katherine B. Peters, and Hasan Hobbs. “Computer-extracted MR imaging features are associated with survival in glioblastoma patients.” J Neurooncol 120, no. 3 (December 2014): 483–88. https://doi.org/10.1007/s11060-014-1580-5.
    Full Text Link to Item
  - Peters, Katherine B., Miranda J. West, Whitney E. Hornsby, Emily Waner, April D. Coan, Frances McSherry, James E. Herndon, Henry S. Friedman, Annick Desjardins, and Lee W. Jones. “Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.” J Neurooncol 120, no. 3 (December 2014): 499–506. https://doi.org/10.1007/s11060-014-1574-3.
    Full Text Link to Item
  - Desjardins, A., J. Herndon, F. McSherry, A. Ravelo, E. Lipp, P. Healy, K. Peters, et al. “AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12–13. https://doi.org/10.1093/neuonc/nou237.20.
    Full Text
  - Desjardins, A., J. Herndon, F. McSherry, A. Ravelo, E. Lipp, P. Healy, S. Boulton, et al. “AT-19 * SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12–v12. https://doi.org/10.1093/neuonc/nou237.19.
    Full Text
  - Ranjan, T., K. B. Peters, G. Vlahovic, J. Watts, S. Dutton, S. Boulton, E. Lipp, et al. “AT-48 * A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v19–v19. https://doi.org/10.1093/neuonc/nou237.47.
    Full Text
  - Desjardins, A., J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol 16 Suppl 3 (July 2014): iii43. https://doi.org/10.1093/neuonc/nou209.5.
    Full Text Link to Item
  - Crowgey, Theresa, Katherine B. Peters, Whitney E. Hornsby, Amy Lane, Frances McSherry, James E. Herndon, Miranda J. West, Christina L. Williams, and Lee W. Jones. “Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.” Appl Physiol Nutr Metab 39, no. 6 (June 2014): 724–29. https://doi.org/10.1139/apnm-2013-0380.
    Full Text Link to Item
  - Daras, Mariza, Christina Cone, and Katherine B. Peters. “Tumor progression and transformation of low-grade glial tumors associated with pregnancy.” J Neurooncol 116, no. 1 (January 2014): 113–17. https://doi.org/10.1007/s11060-013-1261-9.
    Full Text Link to Item
  - Peters, K. B., and S. Turner. “Acquired stuttering due to recurrent anaplastic astrocytoma.” Bmj Case Reports 2013 (December 1, 2013).
  - Peters, Katherine B., and Scott Turner. “Acquired stuttering due to recurrent anaplastic astrocytoma.” Bmj Case Rep 2013 (November 19, 2013). https://doi.org/10.1136/bcr-2013-009562.
    Full Text Link to Item
  - Sampson, J. H., A. Desjardins, K. B. Peters, T. Ranjan, G. Vlahovic, D. Lally-Goss, S. Threatt, et al. “107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” Neurosurgery 60 Suppl 1 (August 2013): 155. https://doi.org/10.1227/01.neu.0000432699.02392.a4.
    Full Text Link to Item
  - Cabrera, Alvin R., Kyle C. Cuneo, Annick Desjardins, John H. Sampson, Frances McSherry, James E. Herndon, Katherine B. Peters, et al. “Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.” Int J Radiat Oncol Biol Phys 86, no. 5 (August 1, 2013): 873–79. https://doi.org/10.1016/j.ijrobp.2013.04.029.
    Full Text Link to Item
  - Lou, Emil, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon, et al. “Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.” Cancer Med 2, no. 2 (April 2013): 185–95. https://doi.org/10.1002/cam4.58.
    Full Text Open Access Copy Link to Item
  - Reardon, D. A., J. E. Herndon, K. B. Peters, A. Desjardins, A. Coan, E. Lou, A. L. Sumrall, et al. “Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.” Br J Cancer 107, no. 9 (October 23, 2012): 1481–87. https://doi.org/10.1038/bjc.2012.415.
    Full Text Open Access Copy Link to Item
  - Reardon, David A., Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, et al. “Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.” Cancer 118, no. 19 (October 1, 2012): 4759–67. https://doi.org/10.1002/cncr.26541.
    Full Text Link to Item
  - Lou, Emil, Ashley L. Sumrall, Scott Turner, Katherine B. Peters, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, et al. “Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.” J Neurooncol 109, no. 1 (August 2012): 63–70. https://doi.org/10.1007/s11060-012-0861-0.
    Full Text Link to Item
  - Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, et al. “Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.” J Neurooncol 108, no. 3 (July 2012): 499–506. https://doi.org/10.1007/s11060-012-0848-x.
    Full Text Link to Item
  - Lou, Emil, Ashley L. Sumrall, Thomas J. Cummings, David N. Korones, Susan A. Weaver, and Katherine B. Peters. “Disseminated Intracranial Ewing's Sarcoma in an Adult: A Rare and Difficult Diagnosis.” Case Rep Oncol 5, no. 2 (May 2012): 325–31. https://doi.org/10.1159/000339721.
    Full Text Link to Item
  - Cuneo, Kyle C., James J. Vredenburgh, John H. Sampson, David A. Reardon, Annick Desjardins, Katherine B. Peters, Henry S. Friedman, Christopher G. Willett, and John P. Kirkpatrick. “Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.” Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 2018–24. https://doi.org/10.1016/j.ijrobp.2010.12.074.
    Full Text Link to Item
  - Desjardins, Annick, David A. Reardon, April Coan, Jennifer Marcello, James E. Herndon, Leighann Bailey, Katherine B. Peters, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab and daily temozolomide for recurrent glioblastoma.” Cancer 118, no. 5 (March 1, 2012): 1302–12. https://doi.org/10.1002/cncr.26381.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, et al. “Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.” J Neurooncol 107, no. 1 (March 2012): 155–64. https://doi.org/10.1007/s11060-011-0722-2.
    Full Text Link to Item
  - Reardon, David A., James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, et al. “Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.” J Neurooncol 107, no. 1 (March 2012): 213–21. https://doi.org/10.1007/s11060-011-0740-0.
    Full Text Link to Item
  - Reardon, David A., Andrew D. Norden, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, John H. Sampson, et al. “Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.” J Neurooncol 106, no. 2 (January 2012): 409–15. https://doi.org/10.1007/s11060-011-0687-1.
    Full Text Link to Item
  - Vredenburgh, James J., Annick Desjardins, John P. Kirkpatrick, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, et al. “Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.” Int J Radiat Oncol Biol Phys 82, no. 1 (January 1, 2012): 58–66. https://doi.org/10.1016/j.ijrobp.2010.08.058.
    Full Text Link to Item
  - Desjardins, Annick, David A. Reardon, Katherine B. Peters, Stevie Threatt, April D. Coan, James E. Herndon, Allan H. Friedman, Henry S. Friedman, and James J. Vredenburgh. “A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 601–6. https://doi.org/10.1007/s11060-011-0627-0.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” Cancer 117, no. 23 (December 1, 2011): 5351–58. https://doi.org/10.1002/cncr.26188.
    Full Text Link to Item
  - Reardon, David A., James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, and Henry S. Friedman. “Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 621–27. https://doi.org/10.1007/s11060-011-0631-4.
    Full Text Link to Item
  - Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, Sridharan Gururangan, Julie Norfleet, Henry S. Friedman, and James J. Vredenburgh. “PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.” Neuro Oncology 13 (November 1, 2011): 90–90.
    Link to Item
  - Peters, Katherine B., April D. Coan, Miranda J. West, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Henry S. Friedman, and Lee W. Jones. “PROGNOSTIC IMPORTANCE OF QUALITY OF LIFE AND FATIGUE IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA.” Neuro Oncology 13 (November 1, 2011): 123–123.
    Link to Item
  - Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, John P. Kirkpatrick, James E. Herndon, April D. Coan, et al. “THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.” Neuro Oncology 13 (November 1, 2011): 89–90.
    Link to Item
  - Cuneo, K. C., A. R. Cabrera, J. Sampson, K. Allen, E. Duffy, J. J. Vredenburgh, K. B. Peters, Z. Chang, A. Desjardins, and J. P. Kirkpatrick. “Bevacizumab and Radiosurgery for Recurrent Malignant Glioma: Toxicity Results from a Prospective Pilot Study.” International Journal of Radiation Oncology*Biology*Physics 81, no. 2 (October 2011): S185–S185. https://doi.org/10.1016/j.ijrobp.2011.06.330.
    Full Text
  - Lou, Emil, Scott Turner, Ashley Sumrall, David A. Reardon, Annick Desjardins, Katherine B. Peters, John H. Sampson, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.” J Clin Oncol 29, no. 28 (October 1, 2011): e739–42. https://doi.org/10.1200/JCO.2011.36.1865.
    Full Text Link to Item
  - Turner, Scott G., Katherine B. Peters, James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, and David A. Reardon. “Everolimus tablets for patients with subependymal giant cell astrocytoma.” Expert Opin Pharmacother 12, no. 14 (October 2011): 2265–69. https://doi.org/10.1517/14656566.2011.601742.
    Full Text Link to Item
  - Vargo, J. A., B. M. Snelling, E. R. Ghareeb, K. John, J. N. Frame, J. H. Schmidt, and K. B. Peters. “Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.” J Neurooncol 104, no. 2 (September 2011): 595–98. https://doi.org/10.1007/s11060-010-0519-8.
    Full Text Link to Item
  - Ruden, Emily, David A. Reardon, April D. Coan, James E. Herndon, Whitney E. Hornsby, Miranda West, Diane R. Fels, et al. “Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.” J Clin Oncol 29, no. 21 (July 20, 2011): 2918–23. https://doi.org/10.1200/JCO.2011.34.9852.
    Full Text Link to Item
  - Peters, Katherine B., Thomas J. Cummings, and Sridharan Gururangan. “Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I.” J Pediatr Hematol Oncol 33, no. 5 (July 2011): e198–201. https://doi.org/10.1097/MPH.0b013e318205e230.
    Full Text Link to Item
  - Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, John P. Kirkpatrick, et al. “The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.” Clin Cancer Res 17, no. 12 (June 15, 2011): 4119–24. https://doi.org/10.1158/1078-0432.CCR-11-0120.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, Katherine Peters, Sridharan Gururangan, John Sampson, Jeremy N. Rich, Roger McLendon, et al. “Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” J Neurooncol 103, no. 2 (June 2011): 371–79. https://doi.org/10.1007/s11060-010-0403-6.
    Full Text Link to Item
  - Gandhi, Nishiena S., Richard L. Skolasky, Katherine B. Peters, Richard T. Moxley, Jason Creighton, Heidi Vornbrock Roosa, Ola A. Selnes, Justin McArthur, and Ned Sacktor. “A comparison of performance-based measures of function in HIV-associated neurocognitive disorders.” J Neurovirol 17, no. 2 (April 2011): 159–65. https://doi.org/10.1007/s13365-011-0023-8.
    Full Text Link to Item
  - Reardon, David A., Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.” J Natl Compr Canc Netw 9, no. 4 (April 2011): 414–27. https://doi.org/10.6004/jnccn.2011.0038.
    Full Text Link to Item
  - Peters, Katherine B., Thomas E. Coyle, James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, and David A. Reardon. “Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.” J Neurooncol 101, no. 1 (January 2011): 155–59. https://doi.org/10.1007/s11060-010-0239-0.
    Full Text Link to Item
  - Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, et al. “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.” J Neurooncol 101, no. 1 (January 2011): 57–66. https://doi.org/10.1007/s11060-010-0217-6.
    Full Text Link to Item
  - Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, J. E. Herndon, J. Marcello, L. Bailey, S. Threatt, and H. S. Friedman. “Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2023–2023. https://doi.org/10.1200/jco.2010.28.15_suppl.2023.
    Full Text
  - Peters, Katherine B., Roger McLendon, Michael A. Morse, and James J. Vredenburgh. “Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.” Case Rep Oncol 3, no. 1 (April 8, 2010): 93–97. https://doi.org/10.1159/000307468.
    Full Text Link to Item
  - Jones, Lee W., Marina Mourtzakis, Katherine B. Peters, Allan H. Friedman, Miranda J. West, Stephanie K. Mabe, William E. Kraus, Henry S. Friedman, and David A. Reardon. “Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.” Oncologist 15, no. 6 (2010): 636–47. https://doi.org/10.1634/theoncologist.2009-0265.
    Full Text Link to Item
  - Peters, K. B., and D. N. Irani. “Connective Tissue, Endocrine, Toxic, and Psychiatric Disorders,” December 1, 2009, 135–43. https://doi.org/10.1016/B978-141602908-3.50020-0.
    Full Text
  - Friedman, H. S., J. J. Vredenburgh, A. Desjardins, D. E. Janney, K. B. Peters, A. H. Friedman, S. Gururangan, and D. A. Reardon. “A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13024.
    Link to Item
  - Kirkpatrick, J. P., J. J. Vredenburgh, A. Desjardins, S. Gururangan, K. B. Peters, S. T. Boulton, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13007.
    Link to Item
  - Reardon, D., A. Desjardins, J. J. Vredenburgh, S. Gururangan, K. B. Peters, and J. A. Norfleet. “Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2046.
    Link to Item
  - Peters, K. B., and D. Schiff. “Neurologic complications of head and neck cancer,” December 1, 2008, 507–21. https://doi.org/10.1007/978-1-59745-412-4_27.
    Full Text
  - Peters, Katherine B., and J Martin Brown. “Tirapazamine: a hypoxia-activated topoisomerase II poison.” Cancer Res 62, no. 18 (September 15, 2002): 5248–53.
    Link to Item
  - Peters, K. B., H. Wang, J. M. Brown, and G. Iliakis. “Inhibition of DNA replication by tirapazamine.” Cancer Res 61, no. 14 (July 15, 2001): 5425–31.
    Link to Item
  - Caligan, T. B., K. Peters, J. Ou, E. Wang, J. Saba, and A. H. Merrill. “A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples.” Anal Biochem 281, no. 1 (May 15, 2000): 36–44. https://doi.org/10.1006/abio.2000.4555.
    Full Text Link to Item
  - Merrill, A. H., T. B. Caligan, E. Wang, K. Peters, and J. Ou. “Analysis of sphingoid bases and sphingoid base 1-phosphates by high-performance liquid chromatography.” Methods Enzymol 312 (2000): 3–9. https://doi.org/10.1016/s0076-6879(00)12894-0.
    Full Text Link to Item
- Book Sections
  - Peters, K. B. “Health-related quality of life in glioma patients.” In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 190–204, 2016. https://doi.org/10.1017/CBO9781107588721.010.
    Full Text
- Journal Issues
  - Ghiaseddin, Ashley, David Reardon, Woody Massey, Alex Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.” Oncologist, February 2018. https://doi.org/10.1634/theoncologist.2017-0501.
    Full Text Link to Item
- Conference Papers
  - Mrugala, M. M., Q. T. Ostrom, S. M. Pressley, J. W. Taylor, A. A. Thomas, J. S. Wefel, S. L. Coven, et al. “The state of neuro-oncology during the COVID-19 pandemic: A worldwide assessment.” In Neuro Oncology Advances, Vol. 3, 2021. https://doi.org/10.1093/noajnl/vdab035.
    Full Text
  - Huang, Raymond Y., Robert J. Young, Benjamin M. Ellingson, Harini Veeraraghavan, Wei Wang, Florent Tixier, Hyemin Um, et al. “Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.” In Neuro Oncol, 22:1822–30, 2020. https://doi.org/10.1093/neuonc/noaa105.
    Full Text Link to Item
  - Lee, J. W. C., M. O. Johnson, J. P. Kirkpatrick, F. McSherry, J. Herndon, E. S. Lipp, A. Desjardins, et al. “Outcomes Following Adjuvant Radiation Therapy in Elderly Patients with Glioblastoma: A Retrospective Single Institution Analysis.” In International Journal of Radiation Oncology*Biology*Physics, 105:E102–E102. Elsevier BV, 2020. https://doi.org/10.1016/j.ijrobp.2019.06.2296.
    Full Text Link to Item
  - Desjardins, Annick, Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret O. Johnson, Stevie Threatt, Chevelle A. Bullock, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Kirkpatrick, J. P., J. Crapo, S. R. Floyd, JA Jr Torok, H. Franklin, C. K. Anders, C. R. Kelsey, et al. “Preserving Neurocognition Without Compromising Tumor Control During Whole-Brain Radiotherapy Therapy In Patients With Numerous Brain Metastases Via A Novel Superoxide Dismutase Mimetic: Initial Safety Lead-In And Design Of A Clinical Trial.” In International Journal of Radiation Oncology Biology Physics, 108:E719–E719, 2020.
    Link to Item
  - Mellinghoff, Ingo K., Katherine B. Peters, Timothy Francis Cloughesy, Howard A. I. I. I. Burris, Elizabeth Anne Maher, Filip Janku, Gregory Michael Cote, et al. “Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Mellinghoff, Ingo K., Martin J. Van den Bent, Jennifer Leigh Clarke, Elizabeth Anne Maher, Katherine B. Peters, Mehdi Touat, John Frederick De Groot, et al. “INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Peters, Katherine B., Adam Louis Cohen, Nicholas A. Butowski, John L. Villano, Pierre Giglio, Tresa McGranahan, Chi Zhang, et al. “BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Peters, Katherine B., John Kirkpatrick, I. Batinic-Haberle, Mary L. Affronti, Sarah Woodring, Deborah Iden, Eric S. Lipp, et al. “Cognitive Outcomes of Phase I Trial of Novel Metalloporphyrin Radioprotectant and Radiosensitizer in Newly Diagnosed High Grade Glioma Patients.” In Supportive Care in Cancer. Springer (part of Springer Nature), 2020.
  - Lew, Meagan V., Yi Ren, Yen P. Lowder, Kristi M. Romero, Jillian C. Thompson, Lauren M. Bohannon, Harvey Cohen, et al. “Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation.” In Blood, 134:1984–1984. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-127264.
    Full Text
  - Mellinghoff, I. K., P. Y. Wen, J. W. Taylor, E. A. Maher, I. Arrillaga-Romany, K. B. Peters, K. Le, F. Tai, L. Steelman, and T. F. Cloughesy. “PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1.” In Neuro Oncology, 21:iii2–iii2. Oxford University Press (OUP), 2019. https://doi.org/10.1093/neuonc/noz126.004.
    Full Text
  - Peters, K. B., J. P. Kirkpatrick, I. Batinic-Haberle, M. L. Affronti, S. Woodring, D. Iden, E. S. Lipp, et al. “First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation.” In International Journal of Radiation Oncology*Biology*Physics, 105:E106–E106. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.06.2305.
    Full Text Link to Item
  - Desjardins, Annick, Matthias Gromeier, James Emmett Herndon, Dina Randazzo, Stevie Threatt, Eric S. Lipp, Elizabeth S. Miller, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.” In Journal of Clinical Oncology, 37:101s-101s. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.2060.
    Full Text Link to Item
  - Mellinghoff, Ingo K., Timothy Francis Cloughesy, Patrick Y. Wen, Jennie Webster Taylor, Elizabeth A. Maher, Isabel Arrillaga, Katherine B. Peters, et al. “A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.” In Journal of Clinical Oncology, 37:2003–2003. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.2003.
    Full Text
  - Peters, Katherine B., Gerald E. Archer, Pamela Norberg, Weihua Xie, Stevie Threatt, Eric S. Lipp, James Emmett Herndon, et al. “Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.” In Journal of Clinical Oncology, 37:e13526–e13526. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e13526.
    Full Text
  - Kang, Jennifer, Christa Swisher, John Kirkpatrick, James Herndon, Eric Lipp, Leslie Thomas, Margaret Johnson, et al. “Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study.” In Neurology, 92:P1–P1. LIPPINCOTT WILLIAMS & WILKINS, 2019.
    Link to Item
  - Kang, J., C. Swisher, John Kirkpatrick, James Herndon, Eric Lipp, Leslie Thomas, Margaret O. Johnson, et al. “Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study.” In Neurology, 92:P1.6-009-P1.6-009. American Academy of Neurology, 2019.
    Link to Item
  - Au, Trang H., Hillevi Bauer, Jyothi Menon, Connor Willis, Eli Iacob, Junjie Ma, Alexandre Watanabe, et al. “Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: Preliminary results from multi-site study in the U.S.” In Journal of Clinical Oncology, 36:16–16. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.34_suppl.16.
    Full Text
  - Johnson, Margaret, John Kirkpatrick, Mallika Weant, Zachary Vaslow, Eric Lipp, James Herndon, Frances McSherry, et al. “TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS.” In Neuro Oncology, 20:vi117–vi117. OXFORD UNIV PRESS INC, 2018. https://doi.org/10.1093/neuonc/noy148.487.
    Full Text Link to Item
  - Randazzo, Dina, John Kirkpatrick, Frances McSherry, James Herndon, Mary Affronti, Margaret Johnson, Zachary Vaslow, et al. “PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS.” In Neuro Oncology, 20:vi217–vi217. OXFORD UNIV PRESS INC, 2018. https://doi.org/10.1093/neuonc/noy148.899.
    Full Text Link to Item
  - Vaslow, Zachary, John Kirkpatrick, Mary Affronti, Patrick Healy, James Herndon, Eric Lipp, Leslie Thomas, et al. “CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS.” In Neuro Oncology, 20:vi239–vi239. OXFORD UNIV PRESS INC, 2018. https://doi.org/10.1093/neuonc/noy148.990.
    Full Text Link to Item
  - Affronti, Mary, Dina Randazzo, Sarah Woodring, Frances McSherry, Patrick Healy, James Herndon, Mallika Weant, et al. “REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS.” In Neuro Oncology, 20:218–218. OXFORD UNIV PRESS INC, 2018.
    Link to Item
  - Ashley, David, Annick Desjardins, Matthias Gromeier, Andrea Muscat, James Herndon, Allan Friedman, Henry Friedman, et al. “INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES.” In Neuro Oncology, 20:7–7. OXFORD UNIV PRESS INC, 2018.
    Link to Item
  - Batich, Kristen, David Ashley, Gary Archer, Luis Sanchez-Perez, Pam Norberg, Kendra Congdon, James Herndon, et al. “ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL.” In Neuro Oncology, 20:234–234. OXFORD UNIV PRESS INC, 2018.
    Link to Item
  - Mellinghoff, Ingo K., Marta Penas-Prado, Katherine B. Peters, Timothy Francis Cloughesy, Howard A. Burris, Elizabeth A. Maher, Filip Janku, et al. “Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.” In Journal of Clinical Oncology, 36:2002–2002. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2002.
    Full Text
  - Nayak, Lakshmi, Timothy Smith, Sarah C. Gaffey, Katherine B. Peters, Jennifer Leigh Clarke, Justin T. Jordan, John Frederick De Groot, et al. “Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.” In Journal of Clinical Oncology, 36:2037–2037. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2037.
    Full Text
  - Reardon, David A., Lakshmi Nayak, Katherine B. Peters, Jennifer Leigh Clarke, Justin T. Jordan, John Frederick De Groot, Phioanh Leia Nghiemphu, et al. “Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.” In Journal of Clinical Oncology, 36:2006–2006. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2006.
    Full Text
  - Inamullah, Ovais, John Kirkpatrick, Patrick Healy, Eric Lipp, Margaret Johnson, David Ashley, Dina Randazzo, Henry Friedman, and Katherine Peters. “Adult Pilocytic Astrocytoma: Clinical Management and Prognostic Factors.” In Neurology, 90:P6–P6. LIPPINCOTT WILLIAMS & WILKINS, 2018.
    Link to Item
  - Vaslow, Zachary, Katherine Peters, John Kirkpatrick, Frances McSherry, James Herndon, Eric Lipp, Margaret O. Johnson, et al. “Long-term outcomes of adult patients with ependymoma.” In Neurology, 90:P6–P6. American Academy of Neurology, 2018.
    Link to Item
  - Inamullah, O., John Kirkpatrick, Patrick Healy, Eric Lipp, Margaret Johnson, David Ashley, Dina Randazzo, Henry Friedman, and Katherine Peters. “Adult pilocytic astrocytoma: clinical management and prognostic factors.” In Neurology, 90:P6.158-P6.158. American Academy of Neurology, 2018.
    Link to Item
  - Dunn-Pirio, Anastasie, Sarah Woodring, Sujata Panta, Eric S. Lipp, Patrick Healy, James E. Herndon, Eric Fountain, et al. “PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS.” In Neuro Oncology, 19:168–168. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Gruslova, Aleksandra, Yichu Liu, Patrick Wen, Katherine B. Peters, James Vredenburgh, Felix Bokstein, Deborah T. Blumenthal, et al. “BIOMARKER ANALYSIS SUPPORTS THE VB-111 DUAL MECHANISM OF ACTION.” In Neuro Oncology, 19:26–26. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS.” In Neuro Oncology, 19:170–170. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB.” In Neuro Oncology, 19:206–206. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Randazzo, Dina, Frances McSherry, James E. Herndon, Mary Lou Affronti, Patrick Healy, Eric S. Lipp, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA.” In Neuro Oncology, 19:202–202. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Desjardins, Annick, Dina Randazzo, Katherine B. Peters, Margaret O. Johnson, Woody Massey, James E. Herndon, Frances McSherry, et al. “PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM).” In Neuro Oncology, 19:vi14–vi14. OXFORD UNIV PRESS INC, 2017. https://doi.org/10.1093/neuonc/nox168.871.
    Full Text Link to Item
  - Weant, Mallika P., John Kirkpatrick, Margaret O. Johnson, Ashley Dunn-Pirio, Patrick Healy, James E. Herndon, Eric Lipp, et al. “PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA.” In Neuro Oncology, 19:vi217–vi217. Oxford University Press (OUP), 2017. https://doi.org/10.1093/neuonc/nox168.878.
    Full Text Link to Item
  - Brenner, Andrew Jacob, Patrick Y. Wen, James J. Vredenburgh, Katherine B. Peters, Deborah T. Blumenthal, Laurence S. Freedman, Bernice Oberman, et al. “Treatment through progression with ofranogene obadenovec (VB-111), an anti-cancer viral therapy, significantly attenuates tumor growth in recurrent GBM: Individual phase 2 patient data.” In Journal of Clinical Oncology, 35:2055–2055. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.2055.
    Full Text
  - Desjardins, Annick, John H. Sampson, Gordana Vlahovic, Katherine B. Peters, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).” In Journal of Clinical Oncology, 35:e13533–e13533. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e13533.
    Full Text Link to Item
  - Peters, Katherine B., Stevie Threatt, Patrick Healy, James Emmett Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Gordana Vlahovic, Henry S. Friedman, and Annick Desjardins. “Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.” In Journal of Clinical Oncology, 35:e21636–e21636. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.e21636.
    Full Text Link to Item
  - Randazzo, Dina, Annick Desjardins, Vidyalakshmi Chandramohan, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Stevie Threatt, et al. “Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.” In Journal of Clinical Oncology, 35:e13532–e13532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.e13532.
    Full Text Link to Item
  - Dunn-Pirio, Anastasie, Katherine Peters, Dina Randazzo, Hentry Friedman, Patrick Healy, James Herndon, Elizabeth Reap, et al. “Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.” In Neurology, 88:S41–S41. American Academy of Neurology, 2017.
    Link to Item
  - Mazurowski, M. A., K. Clark, N. M. Czarnek, P. Shamsesfandabadi, K. B. Peters, and A. Saha. “Radiogenomic analysis of lower grade glioma: A pilot multi-institutional study shows an association between quantitative image features and tumor genomics.” In Progress in Biomedical Optics and Imaging Proceedings of Spie, Vol. 10134, 2017. https://doi.org/10.1117/12.2255579.
    Full Text
  - Randazzo, Dina, Frances McSherry, James Herndon, Mary Lou Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A CROSS-SECTIONAL STUDY OF DISTRESS THROUGHOUT THE DISEASE TRAJECTORY IN PRIMARY BRAIN TUMOR PATIENTS.” In Neuro Oncology, 18:160–160. OXFORD UNIV PRESS INC, 2016.
    Link to Item
  - Affronti, Mary Lou, Sarah Woodring, Karen Allen, John Kirkpatrick, Katherine B. Peters, James E. Herndon, Frances McSherry, et al. “Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).” In Support Care Cancer, 24:4365–75, 2016. https://doi.org/10.1007/s00520-016-3276-1.
    Full Text Link to Item
  - Brenner, Andrew Jacob, Yael Chava Cohen, James J. Vredenburgh, Katherine B. Peters, Lakshmi Nayak, Deborah T. Blumenthal, Felix Bokstein, et al. “Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.” In Journal of Clinical Oncology, 34:2074–2074. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2074.
    Full Text
  - Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.” In Journal of Clinical Oncology, 34:2061–2061. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2061.
    Full Text Link to Item
  - Peters, Katherine B., Sarah Woodring, Patrick Healy, James Emmett Herndon, Eric S. Lipp, Janet Minchew, Ben Zalutsky, et al. “Baseline cognitive function to predict survival in patients with glioblastoma.” In Journal of Clinical Oncology, 34:10125–10125. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.10125.
    Full Text Link to Item
  - Reardon, David A., John Frederick De Groot, Howard Colman, Justin T. Jordan, Mariza Daras, Jennifer Leigh Clarke, Phioanh Leia Nghiemphu, Sarah C. Gaffey, and Katherine B. Peters. “Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).” In Journal of Clinical Oncology, 34:2010–2010. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2010.
    Full Text
  - Vlahovic, Gordana, Gerald E. Archer, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, Patrick Healy, et al. “Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 34:e13518–e13518. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e13518.
    Full Text Link to Item
  - Czarnek, N. M., K. Clark, K. B. Peters, L. M. Collins, and M. A. Mazurowski. “Radiogenomics of glioblastoma: A pilot multi-institutional study to investigate a relationship between tumor shape features and tumor molecular subtype.” In Progress in Biomedical Optics and Imaging Proceedings of Spie, Vol. 9785, 2016. https://doi.org/10.1117/12.2217084.
    Full Text
  - Mazurowski, M. A., N. M. Czarnek, L. M. Collins, K. B. Peters, and K. Clark. “Predicting outcomes in glioblastoma patients using computerized analysis of tumor shape - Preliminary data.” In Progress in Biomedical Optics and Imaging Proceedings of Spie, Vol. 9785, 2016. https://doi.org/10.1117/12.2217098.
    Full Text
  - Mowery, Y. M., G. J. Kim, A. Wright, A. Desjardins, K. B. Peters, G. Vlahovic, H. S. Friedman, J. H. Sampson, and J. P. Kirkpatrick. “Outcomes for Patients With Intracranial Meningiomas Treated With Radiation therapy and Bevacizumab: A Single-Institution Retrospective Analysis.” In International Journal of Radiation Oncology*Biology*Physics, 93:E104–E104. Elsevier BV, 2015. https://doi.org/10.1016/j.ijrobp.2015.07.813.
    Full Text
  - Ghiaseddin, Ashley, David Reardon, Woody Massey, Alexandra Mannerino, Eric Lipp, James Herndon, Frances McSherry, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” In Journal of Clinical Oncology, 33:104s-104s. American Society of Clinical Oncology, 2015.
    Link to Item
  - Kim, Jung-Young, Sarah Woodring, Mary Lou Affronti, Dina Randazzo, Frances McSherry, James Emmett Herndon, Eric S. Lipp, et al. “Secondary cancers in long-term survivors of primary glioblastoma.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” In Journal of Clinical Oncology, 33:2068–2068. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2068.
    Full Text
  - Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Woody C. Massey, Eric S. Lipp, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” In Journal of Clinical Oncology, 33:2067–2067. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2067.
    Full Text
  - Friedman, Henry S., Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Sarah Woodring, Eric S. Lipp, et al. “Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).” In Journal of Clinical Oncology, 33:e13004–e13004. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13004.
    Full Text
  - Ghiaseddin, Ashley, David A. Reardon, Woody Massey, Alexandra Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” In Journal of Clinical Oncology, 33:2034–2034. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2034.
    Full Text
  - Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 33:e13030–e13030. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13030.
    Full Text
  - Peters, Katherine, Mary Lou Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McSherry, James Herndon, et al. “Placebo-controlled, double-blind, randomized pilot study to evaluate the effects of low-dose naltrexone on quality of life and fatigue in newly diagnosed high-grade glioma.” In Neurology, 84:P4–P4, 2015.
    Link to Item
  - Peters, Katherine, Mary Lou Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McSherry, James Herndon, et al. “Placebo-controlled, double-blind, randomized pilot study to evaluate the effects of low-dose naltrexone on quality of life and fatigue in newly diagnosed high-grade glioma.” In Neurology, 84:P4–P4, 2015.
    Link to Item
  - Randazzo, D., M. Affronti, E. Lipp, F. McSherry, J. Herndon, C. Flahiff, E. Miller, et al. “QL-21 SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS.” In Neuro Oncology, 16:v182–83. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou269.20.
    Full Text Link to Item
  - Randazzo, Dina, Mary L. Affronti, Eric Lipp, Frances McSherry, James Herndon, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and alternative medicine in the primary brain tumor population and its association with health-related quality of life.” In Supportive Care in Cancer, 22:S191–S191. Springer (part of Springer Nature), 2014.
    Link to Item
  - Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Jason Watts, Stevie Threatt, et al. “Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2106–TPS2106. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2106.
    Full Text
  - Friedman, Henry S., James Emmett Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.” In Journal of Clinical Oncology, 32:2082–2082. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.2082.
    Full Text
  - Peters, Katherine B., Sarah Woodring, Mary Lou Affronti, Frances McSherry, James Emmett Herndon, Annick Desjardins, Tulika Ranjan, Gordana Vlahovic, Allan H. Friedman, and Henry S. Friedman. “Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.” In Journal of Clinical Oncology, 32:9519–9519. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.9519.
    Full Text
  - Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Sharon Norman, Annick Desjardins, Katherine B. Peters, Tulika Ranjan, et al. “Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 32:3069–3069. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3069.
    Full Text
  - Desjardins, Annick, J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma(GBM): Preliminary results of the Phase I clinical trial.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-CT416.
    Full Text Link to Item
  - Vlahovic, Gordana, Annick Desjardins, Katy Peters, Tulika Ranjan, James Herndon, Allan Friedman, Henry Friedman, et al. “FEASIBILITY AND SAFETY STUDY OF GBM STEM CELL TUMOR AMPLIFIED RNA IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 15:73–74. OXFORD UNIV PRESS INC, 2013.
    Link to Item
  - Brenner, Andrew Jacob, Yael Cohen, James J. Vredenburgh, Katherine B. Peters, Eyal Breitbart, Livnat Bangio, Naamit Sher, Dror Harats, and Patrick Y. Wen. “Phase I/II dose-escalation study of VB-111, an antiangiogenic gene therapy, in patients with recurrent glioblastoma multiforme.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Lindhorst, Scott Michael, Frances McSherry, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Ranjan, Tulika, Katherine B. Peters, Gordana Vlahovic, Lloyd M. Alderson, James Emmett Herndon, Frances McSherry, Stevie Threatt, et al. “Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Weitzel, Douglas, Kathleen Ashcraft, Chunlei Liu, Wei Li, Anne Buckley, Ramona Rodriguez, William Wetzel, et al. “RADIOPROTECTION OF BRAIN WHITE MATTER BY THE CATALYTIC MnSOD MIMIC/ANTIOXIDANT, BMX-001.” In Neuro Oncology, 15:5–6. OXFORD UNIV PRESS INC, 2013.
    Link to Item
  - Levacic, Danijela, and Katherine Peters. “Characterization of Radiation Necrosis in Long-Term Survivors (LTS) of Primary Glioblastoma.” In Neurology, Vol. 80. LIPPINCOTT WILLIAMS & WILKINS, 2013.
    Link to Item
  - Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31, 2013.
    Link to Item
  - Affronti, Mary Lou, Sarah Woodring, James E. Herndon, Frances McSherry, Katherine B. Peters, Henry S. Friedman, Annick Desjardins, et al. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” In Neuro Oncology, 14:156–156. OXFORD UNIV PRESS INC, 2012.
    Open Access Copy Link to Item
  - Alderson, Lloyd M., Annick Desjardins, Tulika Ranjan, Katherine B. Peters, Henry S. Friedman, and James J. Vredenburgh. “BEVACIZUMAB GIVEN WITH TEMOZOLOMIDE AND RADIATION THERAPY (RT) IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) REDUCES THE CHANCE OF EARLY RADIOLOGIC PROGRESSION.” In Neuro Oncology, 14:81–81. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Desjardins, Annick, Katherine B. Peters, James E. Herndon, Leigh Ann Bailey, Lloyd M. Alderson, Tulika Ranjan, John H. Sampson, et al. “NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL (R) FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY.” In Neuro Oncology, 14:104–104. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Peters, Katherine B., David A. Reardon, James J. Vredenburgh, Annick Desjardins, James E. Herndon, April Coan, Frances McSherry, et al. “VORINOSTAT, BEVACIZUMAB, AND METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE GLIOMA: A PHASE I/II CLINICAL TRIAL.” In Neuro Oncology, 14:81–81. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Peters, Katherine B., Sarah Woodring, James E. Herndon, Frances McSherry, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON NEUROCOGNITION.” In Neuro Oncology, 14:62–62. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Peters, Katherine B., Sarah Woodring, James E. Herndon, Frances McSherry, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON QUALITY OF LIFE.” In Neuro Oncology, 14:158–158. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Ranjan, Tulika, Annick Desjardins, Katherine B. Peters, Lloyd Alderson, John Kirkpatrick, James Herndon, Leighann Bailey, et al. “PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” In Neuro Oncology, 14:79–79. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Ranjan, Tulika, Annick Desjardins, Katherine B. Peters, Lloyd Alderson, John Kirkpatrick, James Herndon, Leighann Bailey, et al. “LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” In Neuro Oncology, 14:81–82. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Desjardins, Annick, James J. Vredenburgh, Katherine B. Peters, Stevie Threatt, James Emmett Herndon, John Howard Sampson, Allan H. Friedman, Henry S. Friedman, and David A. Reardon. “Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Friedman, Henry S., Annick Desjardins, Katherine B. Peters, David A. Reardon, John Kirkpatrick, James Emmett Herndon, April D. Coan, et al. “The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Peters, Katherine B., James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, James Emmett Herndon, April D. Coan, Frances McSherry, et al. “Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Vredenburgh, James J., Annick Desjardins, Katherine B. Peters, David A. Reardon, James Emmett Herndon, April D. Coan, John Kirkpatrick, et al. “Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Sumrall, Ashley L., James J. Vredenburgh, Annick Desjardins, David A. Reardon, Henry S. Friiedman, and Katherine B. Peters. “CHEMORADIATION-INDUCED THROMBOCYTOPENIA IMPACTS MORBIDITY AND MORTALITY IN NEWLY-DIAGNOSED HIGH-GRADE GLIOMA PATIENTS.” In Neuro Oncology, 13:53–53. OXFORD UNIV PRESS INC, 2011.
    Link to Item
  - Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, John P. Kirkpatrick, Henry S. Friedman, and James J. Vredenburgh. “SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS.” In Neuro Oncology, 12:77–77. OXFORD UNIV PRESS INC, 2010.
    Link to Item
  - Desjardins, Annick, Katherine B. Peters, James J. Vredenburgh, Henry S. Friedman, and David A. Reardon. “DASATINIB (SPRYCEL) AND ERLOTINIB (TARCEVA) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE 1 TRIAL.” In Neuro Oncology, 12:51–51. OXFORD UNIV PRESS INC, 2010.
    Link to Item
  - Peters, Katherine B., David A. Reardon, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “CHARACTERIZATION OF LONG-TERM SURVIVORS OF PRIMARY GLIOBLASTOMA MULTIFORME AND THEIR USE OF PSYCHOACTIVE MEDICATIONS.” In Neuro Oncology, 12:59–60. OXFORD UNIV PRESS INC, 2010.
    Link to Item
  - Peters, Katherine B., David A. Reardon, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “RETROSPECTIVE ANALYSIS OF INSOMNIA IN RECURRENT GLIOMA PATIENTS AND ITS ASSOCIATION WITH DEXAMETHASONE AND ANTI-EPILEPTICS.” In Neuro Oncology, 12:104–104. OXFORD UNIV PRESS INC, 2010.
    Link to Item
  - Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Katherine B. Peters, Julie A. Norfleet, Allan H. Friedman, and Henry S. Friedman. “PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTS.” In Neuro Oncology, 11:905–905. OXFORD UNIV PRESS INC, 2009.
    Link to Item
  - Reardon, David A., James J. Vredenburgh, Annick Desjardins, Dorothea E. Janney, Katherine B. Peters, Allan H. Friedman, Sridharan Gururangan, and Henry S. Friedman. “A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA.” In Neuro Oncology, 11:946–946. OXFORD UNIV PRESS INC, 2009.
    Link to Item
  - Reardon, David A., James L. Vredenburgh, Annick Desjardins, Sridharan Gururangan, Katherine B. Peters, and Susan T. Boulton. “PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA.” In Neuro Oncology, 11:946–946. OXFORD UNIV PRESS INC, 2009.
    Link to Item
  - Kirkpatrick, J. P., J. J. Vredenburgh, A. Desjardins, S. Gururangan, K. B. Peters, S. T. Boulton, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. E. Herndon, J. Kirkpatrick, S. Gururangan, L. Bailey, A. H. Friedman, and H. S. Friedman. “Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Reardon, D., A. Desjardins, J. J. Vredenburgh, S. Gururangan, K. B. Peters, and J. A. Norfleet. “Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Desjardins, Annick, David A. Reardon, Katherine B. Peters, James Herndon, John Kirkpatrick, Sridharan Gururangan, John H. Sampson, Allan H. Friedman, Henry Friedman, and James J. Vredenburgh. “BEVACIZUMAB (BV) IN COMBINATION TO TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A PHASE 2 TRIAL.” In Neuro Oncology, 11:634–634, 2009.
    Link to Item
  - Desjardins, Annick, James J. Vredenburgh, Katherine B. Peters, Allan H. Friedman, Sridharan Gururangan, Henry Friedman, and David A. Reardon. “SUNITINIB PLUS IRINOTECAN FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE I TRIAL.” In Neuro Oncology, 11:633–34, 2009.
    Link to Item
  - Desjardins, Annick, James J. Vredenburgh, Sridharan Gururangan, Katherine B. Peters, Allan H. Friedman, Henry Friedman, and David A. Reardon. “VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY.” In Neuro Oncology, 11:634–634, 2009.
    Link to Item
  - Desjardins, Annick, James J. Vredenburgh, Sridharan Gururangan, Katherine B. Peters, Allan H. Friedman, Henry Friedman, and David A. Reardon. “A PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS.” In Neuro Oncology, 11:633–633, 2009.
    Link to Item
  - Barboriak, Daniel P., Sarah Woodring, Sujata Panta, Eric Lipp, Frances McSherry, James Herndon, Annick Desjardins, Dina Randazzo, Henry Friedman, and Katherin Peters. “Scan-rescan Repeatability of Hippocampal Volume Measurements in Patients with Low-grade Glioma: Comparison of Automated Software Packages.,” n.d.
  - Desjardins, Annick, Dina Randazzo, V. Chandramohan, Katherine B. Peters, Margaret O. Johnson, Steve Threatt, James E. Herndon, et al. “Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma.,” n.d.
  - Desjardins, Annick, Dina Randazzo, V. Chandramohan, Katherine Peters, Margaret O. Johnson, Stevie Threatt, James Herndon, et al. “Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma.,” n.d.
  - Desjardins, Annick, John Sampson, Katherine Peters, Gordana Vlahoci, Dina Randazzo, Stevie Threatt, James Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.,” 33:112s-112s, n.d.
    Link to Item
  - Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Eric Lipp, Woody Massey, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.,” 33:112s-112s, n.d.
    Link to Item
  - Kim, Jung, Sarah Woodring, Mary L. Affronti, Dina Randazzo, Frances McSherry, James Herndon, Eric Lipp, et al. “Secondary cancers in long-term survivors of primary glioblastoma.” In Journal of Clinical Oncology, Vol. 33, n.d.
    Link to Item
  - Peters, Katherine, Mary Affronti, Sarah Woodring, Stevie Threatt, Patrick Healy, James Herndon, Eri Lipp, Dina Randazzo, Annick Desjardins, and Henry Friedman. “Taking sides: importance of tumor laterality in understanding cognitive testing in primary brain tumor patients.,” n.d.
  - Peters, Katherine, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McShwrry, James Herndon, et al. “QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study.” In Neuro Oncology, 17:v192–v192. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov230.20.
    Full Text Link to Item
  - Peters, Katherine, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McShwrry, James Herndon, et al. “QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study.” In Neuro Oncology, 17:v192–v192. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov230.20.
    Full Text Link to Item
  - Peters, Katherine, Patrick Healy, James Herndon, Eric Lipp, Sujata Panta, Dina Randazzo, Gordana Vlahovic, Henry Friedman, and Annick Desjardins. “Perceived cognitive dysfunction at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients.” In Supportive Care in Cancer, 25:S60–S60. Springer (part of Springer Nature), n.d.
  - Peters, Katherine, Stevie Threatt, Patrick Healy, James Herndon, Eric Lipp, Sujata Panta, Dina Randazzo, Henry Friedman, and Annick Desjardsin. “Cognitive performance at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients.” In Supportive Care in Cancer, 26:S162–S162. Springer (part of Springer Nature), n.d. https://doi.org/10.1007/s00520-018-4193-2.
    Full Text
  - Randazzo, Dina, Frances McSherry, James Herndon, Mary L. Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and Alternative Medicine in the Primary Brain Tumor Population and its Association with Health-Related Quality of Life.,” n.d.
  - Randazzo, Dina, Frances McSherry, James Herndon, Mary Lou Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, et al. “QOL-21 Diet and health-related quality of life (HRQoL) in the primary brain tumor population.” In Neuro Oncology, 17:v192–v192. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov230.21.
    Full Text Link to Item
  - Randazzo, Dina, Mary Affronti, Eric Lipp, Frances McSherry, James Hernson, Charlene Flahiff, Elizabeth Miller, et al. “Psychosocial Distress and its Effects on the Health-Related Quality of Life of Primary Brain Tumor Patients.,” n.d.
  - Randazzo, Dina, Mary L. Affronti, Eric Lipp, Frances McSherry, James Herndon, Charlene Flahiff, Sarah Woodring, et al. “Complementary and alternative medicine in the primary brain tumor population and its association with health reported Quality of Life.” In Neurology, 84:S18–S18. American Academy of Neurology, n.d.
    Link to Item
  - Weant, Erin H., Sarah Woodring, Din Randazzo, Henry Friedman, Annick Desjardins, Gordana Vlahovic, Patrick Healy, et al. “Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” In Supportive Care in Cancer, 25:S128–S128. Springer (part of Springer Nature), n.d. https://doi.org/10.1007/s00520-017-3704-x.
    Full Text Link to Item
  - Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.
    Full Text Link to Item
  - Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.
    Full Text Link to Item
Teaching & Mentoring
Recent Courses
- NEUROSUR 404C: Neuro-Oncology 2023
- NEUROSUR 404C: Neuro-Oncology 2022
- NEUROSUR 404C: Neuro-Oncology 2021
Advising & Mentoring
- Fellow: Kristen Batich, Kaleigh Fetcko-Fayad, Avani Mangoli, Katherine Ryan
  Faculty: Mallika Patel, Margaret Johnson, Justin Low
  Resident: Dylan Ryan (Neurology), Eugene Vaios (Radiation Oncology)
  
  Fellowship Since 2012
  
  Danijela Levacic, MD
  
  Adult Neurology
  
  1. Levacic D and Peters, K.B. Characterization of Radiation Necrosis in Long-Term Survivors of Primary Glioblastoma. Abstract NO-12. Annual Meeting of the American Academy of Neurology 2012, March 22^nd.
  
  2. Peters, K., Woodring, S., Affronti, M.L., Threatt, S., Lindhorst, S., Levacic, D., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, A., and Friedman, H.: Neurocognitive dysfunction in newly diagnosed high-grade glioma patients: utilization of standardized computerized neurocognitive testing. Abstract NC-018. 2013 SNO Annual Meeting, November 21-24, 2013, San Francisco, CA. Neuro-Oncol. 15, Suppl. 3: iii73, 2013.
  
  07/2012-06/2013
  
  1 year
  
  Physician, Neuro-Oncology
  
  Baylor Scott & White Cancer Center – Round Rock
  
  Round Rock, TX
  
  Scott Lindhorst, MD
  
  Medical Oncology
  1. Lindhorst, S.M., McSherry, F., Desjardins, A., Friedman, H.S., and Peters, K.B.: Anaylsis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma. Abstract 2090. 2013 ASCO Annual Meeting, May 31-June 4, 2013, McCormick Place, Chicago, IL. J. Clin. Oncol. 31, Suppl. (15S, Part I): 136s, 2013.
  2. Peters, K., Woodring, S., Affronti, M.L., Threatt, S., Lindhorst, S., Levacic, D., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, A., and Friedman, H.: Neurocognitive dysfunction in newly diagnosed high-grade glioma patients: utilization of standardized computerized neurocognitive testing. Abstract NC-018. 2013 SNO Annual Meeting, November 21-24, 2013, San Francisco, CA. Neuro-Oncol. 15, Suppl. 3: iii73, 2013.
  07/2012-06/2013
  
  1 year
  
  Associate Professor of Neurosurgery, Medical University of South Carolina, Charleston, SC
  
  Dina Randazzo, DO
  
  Adult Neurology
  1. Peters, K., Threatt, S., Healy, P. Herndon, J.E. II, Lipp,E., Panta, S., Randazzo, D., Vlahovic, G., Friedman, H.S. and Desjardins, A.: Perceived cognitive dysfunction at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients. Abstract PS060. 2017 MASCC Annual Meeting, June 22-24, 2017, Washington DC.
  2. Barboriak, D.P, Woodring, S., Panta, S., Lipp, E. , McSherry, F. , Herndon, J.E. II, Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B. Scan-rescan Repeatability of Hippocampal Volume Measurements in Patients with Low-grade Glioma: Comparison of Automated Software Packages Presented at American Society of Neuroradiology meeting, June 5, 2018, Vancouver, Canada.
  3. Peters, K.B., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Friedman, H.S., and Desjardins, A.: Cognitive performance at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients. 2018 MASCC Annual Meeting, June 28-30, 2018, Vienna, Austria.
  4. Peters, K.B., Affronti, M.L., Woodring, S., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Desjardins, A., and Friedman, H.S. Taking sides: importance of tumor laterality in understanding cognitive testing in primary brain tumor patients. 2019 MASCC Annual Meeting, June 21-33, 2019, San Francisco, CA.
  5. Peters, K.B., Kirkpatrick J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Lipp, E., Boyd, K., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Crapo, J.: First in human clinical trial of metalloporphyrin dual radioprotectant and radiosensitizer, BMX-001, in newly diagnosed high-grade glioma undergoing concurrent chemoradidation. Poster 2239. 2019 ASTRO Annual Meeting, September 15-18, 2019, Chicago, IL.
  6. Peters, K., Congdon, K., Archer, G., Woodring, S., Jaggers, D., Lipp, E., Healy, P., Herndon, J., Soher, B., Vlahovic, G., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Friedman, A., Ashley, D., Yan, H., and Sampson, J.: Safety of tumor-specific peptide vaccine targeting isocitrate dehydrogenase 1 mutation in recurrent resectable low grade glioma patients. Abstract ATIM-31. Neuro-Oncology 21(Suppl 6):vi8, 2019.
  7. Peters, K., Lipp, E., Broadwater, G., Herndon J. II, Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Affronti, M.: Clinical characteristics of low grade glioma patients with non-canonical IDH1 and IDH2 mutations. Abstract NCOG-38. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii137, 2020.
  8. Randazzo, D.M., Affronti, M.L., Lipp, E., McSherry, F., Herndon, J.E. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, H.F., and Peters, K.B.: Complementary and alternative medicine in the primary brain tumor population and its association with health-related quality of life. Abstract MASCC-0215. 2014 MASCC Annual Meeting, June 26 – 28, 2014, Miami, FL. Supp. Care Cancer 22, Suppl. 1: S191, 2014.
  9. Peters, K., Reardon, D., Randazzo, D., Dutton, S., Edwards, A., Lipp, E., Herndon, J. II, McSherry, F., Desjardins, A., Ranjan, T., Vlahovic, G., and Friedman, H.: Vorinostat and bevacizumab for recurrent high-grade glioma: interim analysis of a phase II clinical trial. Abstract AT-46. 2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL. Neuro-Oncol. 16, Suppl. 5: v128 2014.
  10. Peters, K., Randazzo, D., Affronti, M., Lipp, E., McSherry, F., Herndon, J. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Ranjan, T., Vlahovic, G., Jones, L., and Friedman, H.: Prognostic importance of health-related quality of life and fatigue in newly diagnosed glioblastoma. Abstract QL-20. 2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL. Neuro-Oncol. 16, Suppl. 5: v182, 2014.
  11. Randazzo, D., Affronti, M., Lipp, E., McSherry, F., Herndon, J. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, H., and Peters, K.: Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. Abstract QL-21. 2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL. Neuro-Oncol. 16, Suppl. 5: v182, 2014.
  12. Peters, K.B., Affronti, M.L., Woodring, S., Lipp, E., Healy, P., McSherry, F., Herndon, J.E., Flahiff, C., Miller, E., Freeman, M., Minchew, J., Zalutsky, B., Taylor, B., Boulton, S., Randazzo, D., Desjardins, A., Vlahovic, G., Bigner, D.D., and Friedman, H.S.: Placebo-controlled, double-blind, randomized pilot study to evaluate the effects of low-dose naltrexone on quality of life and fatigue in newly diagnosed high-grade glioma. Abstract P4.210. 2015 AAN Annual Meeting. April 18-25, 2015, Washington, DC.
  1. Randazzo, D., Affronti, M.L., Lipp, E., McSherry, F., Herndon, J.E. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S.B., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, H.S., and Peters, K.B.: Complementary and alternative medicine in the primary brain tumor population and its association with health reported Quality of Life. Abstract S18.007. 2015 AAN Annual Meeting. April 18-25, 2015, Washington, DC.
  2. Desjardins, A., Sampson, J.H., Peters, K.B., Vlahovic, G., Randazzo, D., Threatt, S., Herndon, J.E., Boulton, S., Lally-Goss, D., McSherry, F., Lipp, E.S., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Gromeier, M.M.: Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. Abstract 2068. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  10. Desjardins, A., Peters, K.B., Vlahovic, G., Randazzo, D., Boulton, S., Massey, W.C., Lipp, E.S., Herndon, J.E., Healy, P., Miller, E., Karmali, R.A., and Friedman, H.S.: Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. Abstract 2067. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  
  11. Vlahovic, G., Archer, G.E., Lally-Goss, D., Reap, E., Desjardins, A., Peters, K.B., Randazzo, D., Healy, P., Herndon, J.E., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). Abstract e13030. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  
  12. Kim, J.Y., Woodring, S., Affronti, M.L., Randazzo, D., McSherry, F., Herndon, J.E., Lipp, E.S., Desjardins, A., Vlahovic, G., Friedman, H.S., and Peters, K.B.: Secondary cancers in long-term survivors of primary glioblastoma. Abstract e20616. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  
  13. Randazzo, D.M., McSherry, F., Herndon, J.E., Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H.S., Keir, S.T. and Peters, K.B.: Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. Abstract 9553. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  
  14. Ghiaseddin, A., Reardon, D.R., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E., McSherry, F., Desjardins, A., Randazzo, D.A., Vlahovic, G., Friedman, H.S., and Peters, K.B.: Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. Abstract 2034. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  
  15. Friedman, H.S., Peters, K.B., Vlahovic, G., Randazzo, D., Boulton, S., Woodring, S., Lipp, E.S., Herndon, J.E., Healy, P., Miller, E., Karmali, R.A. and Desjardins, A.: Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG). Abstract e13004. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  
  16. Brownstein, J., Randazzo, D., Kim, G., Peters, K., and Kirkpatrick, J.: A simple kinetic model provides an early prediction of thrombocytopenia in malignant glioma patients treated with radiation and temozolomide. Abstract. 2015 57^th ASTRO Annual Meeting, October 18-22, 2015, San Antonio, TX.
  
  17. Affronti, M.L., Friedman, H.S., Desjardins, A., Vlahovic, G., Randazzo, D.M., Herndon, J.E., McSherry, F., Lipp, E.S., Mannerino, A., Massey, W., Miller, E., Iden, D., Peters, K.B.: Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG). Abstract ATCT-01. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v1, 2015.
  
  18. Weant, M., Dunn-Pirio, A., Peters, K., Vlahovic, G., Randazzo, D., Herndon, J.E. II, Healy, P., Threatt, S., Sampson, J., Friedman, A., Friedman, H., Desjardins, A.: Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. Abstract ATCT-13. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v4, 2015.
  
  19. Vlahovic, G., Archer, G., Reap, E., Ghiaseddin, A., Desjardins, A., Peters, K., Randazzo, D., Healy, P., Herndon, J.E. II, Friedman, A., Friedman, H., Bigner, D., and Sampson, J.: Combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM). Abstract IMCT-19. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v111, 2015.
  
  20. Peters, K., Affronti, M., Woodring, S., Lipp, E., Healy, P., McSherry, F., Herndon, J.E. II, Flahiff, C., Miller, E., Freeman, M., Minchew, J., Zalutsky, B., Taylor, B., Boulton, S., Randazzo, D., Desjardins, A., Vlahovic, G., Bigner, D., and Friedman, H.: Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study. Abstract QOL-20. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v192, 2015.
  
  21. Randazzo, D.M., McSherry, F., Herndon, J.E. II, Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H.S., and Peters, K.B.: Diet and health-related quality of life (HRQoL) in the primary brain tumor population. Abstract QOL-21. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v192, 2015.
  
  22. Desjardins, A. Sampson, J.H., Peters, K.B., Vlahovic, G., Randazzo, D., Threatt, S., Herndon, J.E., Boulton, S., Lally-Goss, D., McSherry, F., Lipp, E.S., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Gromeier, M.: Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).   Abstract 2061. 2016 ASCO Annual Meeting. June 3 – 7, 2016, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 34(15s), 107s, 2016.
  
  23. Peters, K.B., Woodring, S., Healy, P., Herndon, J.E., Lipp, E.S., Minchew, J., Zalutsky, B., Affronti, M., Randazzo, D., Desjardins, A., Vlahovic, G., and Friedman, H.S.: Baseline cognitive function to predict survival in patients with glioblastoma. Abstract 10125. 2016 ASCO Annual Meeting. June 3 – 7, 2016, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 34(15s), 541s, 2016.
  
  24. Vlahovic, G., Archer, G.E., Reap, E. Desjardins, A., Peters, K.B., Randazzo, D., Healy, P., Herndon, J.E., Friedman, A.H., Friedman, H.S., Bigner, D.D. and Sampson, J.H.: Phase 1 trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in paitents with newly-diagnosed glioblastoma multiforme (GBM). Abstract e13518. 2016 ASCO Annual Meeting. June 3 – 7, 2016. Pro. J Clin Oncol. 34(15s), 2016.
  
  25. Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., and Bigner, D.: Phase I dose escalation study of D2C7-IT administered intratumorally via convection-enhanced deliver (CED) for recurrent malignant glioma (MG). Abstract ATIM-18. 2016 SNO Annual Meeting. November 17-20, 2016, Scottsdale, AZ.   Neuro-Oncology 18:vi21, 2016.
  
  26. Peters, K., Affronti, M.L., Woodring, S., Minchew, J., Lipp, E., McSherry, F., Herndon, J., Randazzo, D., Desjardins, A., Vlahovic, G., Friedman, H., and Barboriak, D.: Neurocognition in low-grade gliomas: associations with measurable and perceived impairments. Abstract NCOG-12. 2016 SNO Annual Meeting. November 17-20, 2016, Scottsdale, AZ.   Neuro-Oncology 18:vi122, 2016.
  
  27. Randazzo, D., McSherry, F., Herndon, J., Affronti, M.L., Lipp, E., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H., Keir, S., and Peters, K.: A cross-sectional study of distress throughout disease trajectory in primary brain tumor patients. Abstract QLIF-20. 2016 SNO Annual Meeting. November 17-20, 2016, Scottsdale, AZ.   Neuro-Oncology 18:vi160, 2016.
  
  28. Desjardins, A., Sampson, J.H., Vlahovic, G., Peters, K.B., Randazzo, D., Threatt, S., Herndon, J.E., Bullock, C.A., Miller, E.S., Boulton, S., Lally-Goss, D., McSherry, F., Lipp, E.S., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Gromeier, M.: Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG). Abstract e13533. 2017 ASCO Annual Meeting, June 2-5, 2017, Chicago, IL. J Clin Oncol 35, 2017.
  
  29. Randazzo, D., Desjardins, A., Chandramohan, V., Sampson, J.H., Peters, K.B., Vlahovic, G., Threatt, S., Herndon, J.E., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E.S., Friedman, A.H., and Bigner, D.D.: Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma. Abstract e13532. 2017 ASCO Annual Meeting, June 2-5, 2017, Chicago, IL. J Clin Oncol 35, 2017.
  
  30. Peters, K.B., Threatt, S., Healy, P., Herndon, J.E., Lipp, E.S., Panta, S., Randazzo, D., Vlahovic, G., Friedman, H.S., and Desjardins, A.: Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients. Abstract e21636. 2017 ASCO Annual Meeting, June 2-5, 2017, Chicago, IL. J Clin Oncol 35, 2017.
  
  31. Weant, E., Woodring, S., Randazzo, D.M., Friedman, H.F., Desjardins, A., Vlahovic, G., Healy, P., Herndon, J.E. II , McSherry, F., Lipp, E.,Miller, E., Cone, C., Kim, J.Y., Southerland, C., Brown, C., Carter, M., Johnson, M.P., Peters, K.B, and Affronti, M.L.,: Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. Abstract MASCC-EP178. 2017 MASCC Annual Meeting, June 22-24, 2017, Washington DC. Supp. Care Cancer 25, Suppl. 2: S266, 2017.
  
  32. Desjardins, A., Randazzo, D., Peters, K.B., Johnson, M.O., Massey, W., Herndon, J.E. II, McSherry, F., Lipp, E.S., Nadler, P., Horak, I.D., Friedman, H.S.: Phase 2 Study of SYM004 for Adult Patients with Recurrent Glioblastoma (GBM). Abstract ACTR-64. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi303, 2017.
  
  33. Dunn-Pirio, A., Woodring, S., Panta, S., Lipp, E.S., Healy, P., Herndon, J.E. II, Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: Perampanel for treatment of refractory Seizures in patients with gliomas. Abstract PALL-02. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi168, 2017.
  
  34. Peters, K.B., Affronti, M.L., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Friedman, H.S., Desjardins, A.: Increased fatigue associated with tumor progression in newly diagnosed glioblastoma (gbm) patients. Abstract PALL-10. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi170, 2017.
  
  35. Randazzo, D., McSherry, F., Herndon, J.E. II, Affronti, M.L., Healy, P., Lipp, E.S., Desjardins, A., Friedman, H.S., Peters, K.B.: A single institution’s experience exploring the association of integrative medicine and survivorship in glioblastoma. Abstract QLIF-05. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi202, 2017.
  
  36. Peters, K.B., Affronti, M.L., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Friedman, H.S., Desjardins, A.: Maintenance of health related quality of life (qol) beyond progression in newly diagnosed glioblastoma patients treated with bevacizumab. Abstract QLIF-22. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi206, 2017.
  
  37. Affronti, M.L., Randazzo, D., Peters, K.B., Herndon, S.C., Healy, P., Herndon, J.E., Woodring, S., Hawkins, K., Lipp, E.S., Kohrman, O., Desjardins, A., Vlahovic, G., Friedman, H.S., Kim, J.Y., Miller, E.S., Schneider, S.: Pilot study to describe the trajectory of symptoms and adaptive strategies of adults living with low grade gliomas (lgg). Abstract QLIF-34. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi208, 2017.
  
  38. Johnson, M.O., Kirkpatrick, J.P., Weant, M.P., Dunn-Pirio, A., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: A retrospective, single institution study of central neurocytoma (2004-2016): survival, treatment, and supportive care. Abstract RARE-25. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi215, 2017.
  
  39. Weant, M.P., Kirkpatrick, J., Johnson, M., Dunn-Pirio, A., Healy, P., Herndon, J.E. II, Lipp, E.S., Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma. Abstract RARE-36. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi217, 2017.
  
  40. Vaslow, Z., Peters, K., Kirkpatrick, J., McSherry, F., Herndon, J. II, Lipp, E., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., and Friedman, H.S.: Long-term outcomes of adult patients with ependymoma. Abstract 150. 2018 70^th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.
  
  41. Inamullah, O., Kirkpatrick, J., Healy, P., Lipp, E., Johnson, M., Ashley, D., Randazzo, D., Friedman, H. and Peters, K.: Adult pilocytic astrocytoma: clinical management and prognostic factors. Abstract 158. 2018 70^th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.
  
  42. Peters, K.B., Kirkpatrick, J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Panta, S., Lipp, E., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D. and Crapo, J.: Phase I dose escalation trial of the safety of BMX-001 concurrent with radiation therapy and temozolomide in newly diagnosed patients with high-grade glioma. Abstract ACTR-28. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi17, 2018.
  
  43. Ashley, D., Desjardins, A., Gromeier, M., Muscat, A., Herndon, J., Friedman, A., Friedman, H., McSherry, F., Randazzo, D., Peters, K., Threatt, S., Bullock, C., Miller, E., Boulton, S., Lipp, E., Bigner, D., and Sampson, J.: Intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in malignant glioma patients: assessment of mutational response correlates. Abstract ATIM-27. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi7, 2018.
  
  44. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Thomas, L., Threatt, S., Bullock, C., Herndon, J., Boulton, S., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.: Dose escalation trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract ATIM-36. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi9, 2018.
  
  45. Johnson, M., Kirkpatrick, J., Weant, M., Vaslow, Z., Lipp, E., Herndon, J., McSherry, F., Desjardins, A., Randazzo, D., Friedman, H., Ashley, D., and Peters, K.: Treatment patterns, outcomes and prognostic indicators in elderly patients with glioblastoma: a retrospective single institution analysis. Abstract HOUT-19. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi117, 2018.
  
  46. Randazzo, D., Kirkpatrick, J., McSherry, F., Herndon, J., Affronti, M., Johnson, M., Vaslow, Z., Lipp, E., Desjardins, A., Friedman, H., and Peters, K.: Psychosocial distress in patients with recurrent meningiomas. Abstract QOLP-13. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi217, 2018.
  
  47. Affronti, M., Randazzo, D., Woodring, S., McSherry, F., Healy, P., Herndon, J., Weant, M., Miller, E., Lipp, E., Friedman, H., and Peters, K.: Review and meta-analysis of nausea and vomiting trials for malignant glioma. Abstract QOLP-17. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi218, 2018.
  
  48. Vaslow, Z., Kirkpatrick, J., Affronti, M., Healy, P., Herndon, J., Lipp, E., Thomas, L., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Peters, K.: Clinical and histopathological characteristics of young adults with glioblastoma at diagnosis. Abstract RARE-16. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi239, 2018.
  
  49. Kang, J., Swisher, C., Kirkpatrick, J., Herndon, J. II, Lipp, E., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., and Peters, K.: Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study. 2019 AAN Annual Meeting, May 4-10, 2019, Philadelphia, PA.
  
  50. Desjardins, A., Gromeier, M., Herndon, J.E. II, Randazzo, D., Threatt, S., Lipp, E.S., Miller, E.S., Jackman, J., Bolognesi, D.P., Friedman, A.H., Friedman, H.S., McSherry, F., Peters, K.B., Johnson, M.O., Sampson, J.H., Ashley, D.M., and Bigner, D.D.: Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): experience with retreatment of survivors from the phase I trial. Abstract 2060. 2019 ASCO Annual Meeting, May 31 – June 4, 2019, Chicago, IL. J Clin Oncol 37(15s):101s, 2019.
  
  51. Lee, J.W., Johnson, M.O., Kirkpatrick, J.P., McSherry, F., Herndon, J., Lipp, E., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D., Peters, K.B.: Outcomes following adjuvant radiation therapy in elderly patients with glioblastoma: a retrospective single institution analysis. 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, McCormick Place West, Chicago, IL, September 15 – 18, 2019.
  
  52. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Threatt, S., Bullock, C., Jackman, J., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.: Dose finding and dose expansion trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract ATIM-24. Neuro-Oncology 21(Suppl 6):vi6, 2019.
  
  53. Gromeier, M., Brown, M., Beuabier, N., Yan, H., He, Y., Zhang, G., Desjardins, A., Herndon, J., Bolognesi, D., Friedman, A., Friedman, H., McSherry, F., Lin, X., Wei, Z., Nair, S., Peters, K., Randazzo, D., Sampson, J., McLendon, R., Bigner, D., and Ashley, D.: Tumor mutational burden predicts response to oncolytic polio/rhinovirus recombinant (PVSRIPO) in malignant glioma patients: assessment of transcriptional and immunological correlates. Abstract ATIM-27. Neuro-Oncology 21(Suppl 6):vi7, 2019.
  
  54. Barbour, A., Healy, P., Lipp, E., Herndon, J., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., Kirkpatrick, J., and Peters, K.: Characteristics of short-term survival in patients with glioblastoma: a retrospective analysis. Abstract HOUT-21. Neuro-Oncology 21(Suppl 6):vi116, 2019.
  
  55. Johnson, M., Ramirez, L., Herndon, J., Massey, W., Lipp, E., Affronti, M., Kim, J.-Y., Friedman, H., Desjardins, A., Randazzo, D., Ashley, D., Casarette, D., and Peters, K.: A time-based model of early palliative care intervention in patients with newly diagnosed glioblastoma, a single institution feasibility study. Abstract QOLP-18. Neuro-Oncology 21(Suppl 6):vi201, 2019.
  
  56. Randazzo, D., Jackman, J., Herndon, J., Affronti, M., Lipp, E., Cort, N., Desjardins, A., Johnson, A., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.: Mindfulness meditation practice in malignant glioma patients throughout concomitant radiation and temozolomide: a feasibility study. Abstract QOLP-29. Neuro-Oncology 21(Suppl 6):vi204, 2019.
  
  57. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K.B., Johnson, M.O., Threatt, S., Bullock, C.A., Herndon, J.E. II, Healy, P., Lipp, E.S., Sampson, J.H., Friedman, A.H., Friedman, H.S., Ashley, D.M., and Bigner, D.D.: Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract 2566. 2020 ASCO Virtual Annual Meeting, May 29 – 31, 2020. J Clin Oncol 38(suppl), 2020.
  
  58. Thompson, E., Landi, D., Lipp, E., Balajonda, B., Herndon, J. II, Buckley, E., Flahiff, C., Jaggers, D., Schroeder, K., Randazzo, D., Desjardins, A., Johnson, M., Peters, K., Khasraw, M., Malinzak, M., Mitchell, D., Ashley, D., and Sampson, J.: Peptide vaccine directed to CMV PP65 for treatment of recurrent malignant glioma and medulloblastoma in children and young adults: preliminary results of a phase I trial. Abstract CTIM-21. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii37, 2020.
  
  59. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Landi, D., Khasraw, M., Threatt, S., Bullock, C., Herndon, J. II, Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.: A phase I trial of D2C7-IT in combination with atezolizumab in recurrent WHO grade IV malignant glioma (MG). Abstract CTIM-23. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii38, 2020.
  
  60. Johnson, M., Herndon, J. II, Lipp, E., Affronti, M., Desjardins, A., Bhattacharya, M., Friedman, H., Ashley, D., Peters, K., and Randazzo, D.: Patterns of distress in older patients with glioblastoma: a follow-up to a single institution cross-sectional study of distress in primary brain tumor patients. Abstract NCOG-23. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii134, 2020.
  
  61. Patel, M., Peters, K., Lipp, E., Low, J., Herndon, J. II, Broadwater, G., Johnson, M., Randazzo, D., Kim, J-Y., and Affronti, M.: Olanzapine for refractory chemotherapy-induced nausea and vomiting in malignant glioma patients. Abstract QOLP-05. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii175, 2020.
  
  62. Randazzo, D., Buckley, E., Herndon, J. II, Cort, N., Affronti, M., Lipp, E., Desjardins, A., Johnson, M., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.: A feasibility study utilizing mindfulness meditation during concomitant chemoradiation in malignant glioma patients: health-related quality of life (HRQOL) results. Abstract QOLP-20. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii179, 2020.
  
  63. Peters, K., Randazzo, D., Johnson, M., Kim, J-Y., Patel, M., and Affronti, M.: Engaging patients and caregivers to improve the importance and quality of supportive care research in neuro-oncology. Abstract QOLP-24. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii180, 2020.
  1. Randazzo, D. and Peters, K.B.: Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. CNS Oncol. 5:241-249, 2016.
  2. Randazzo, D.M., McSherry, F., Herndon, J.E. II, Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H.S., Keir, S., and Peters, K.B.: A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population. J. Neurooncol. 134:363-369, 2017.
  3. Ghiaseddin, A., Reardon, D., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E. II, McSherry, F., Desjardins, A., Randazzo, D., Friedman, H.S., and Peters, K.B.: Phase II study of bevacizumab and vorinostat for patients with recurrent World Health Organization Grade 4 malignant glioma. Oncologist, 23:157-e21, 2018.
  4. Desjardins, A., Gromeier, M., Herndon, J.E. II, Beaubier, N., Bolognesi, D.P., Friedman, A.H., Friedman, H.S., McSherry, F., Muscat, A.M., Nair, S., Peters, K.B., Randazzo, D., Sampson, J.H., Vlahovic, G., Harrison, W.T., McLendon, R.E., Ashley, D., and Bigner, D.D.: Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379(2):150-161, 2018.
  5. Dunn-Pirio, A., Woodring, S., Lipp, E., Herndon, J.E. II, Healy, P., Weant, M., Randazzo, D., Desjardins, A., Friedman, H.S., and Peters, K.B.: Adjunctive perampanel for refractory glioma-associated epilepsy. Epilepsy Behav. Case Rep. 10:114-117, 2018.
  6. Affronti, M.L., Randazzo, D., Lipp, E.S., Peters, K.B., Herndon, S.C., Woodring, S., Healy, P., Cone, C.K., Herndon, J.E. II, and Schneider, S.M.: Pilot study to describe the trajectory of symptoms and adaptive strategies of adults living with low-grade glioma. Semin. Oncol. Nurs. 34(5):472-485, 2018.
  7. Desjardins, A., Herndon, J.E. II, McSherry, F., Ravelo, A., Lipp, E.S., Healy, P., Peters, K.B., Sampson, J.H., Randazzo, D., Sommer, N., Friedman, A.H., and Friedman, H.S.: Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. Health Sci. Rep. 2:e114, 2019.
  8. Randazzo, D.M., McSherry, F., Herndon, J.E., Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Boulton, S., Desjardins, A., Ashley, D.M., Friedman, H.S., and Peters, K.B.: Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. Complementary Therapies Clin. Prac. 36:43-48, 2019.
  9. Patel, M.P., Woodring, S., Randazzo, D.M., Friedman, H.S., Desjardins, A., Healy, P., Herndon, J.E. II, McSherry, F., Lipp, E.S., Miller, E., Peters, K.B., and Affronti, M.L.: Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. Supp. Care Cancer. Published online ahead of print August 22, 2019.
  10. Johnson, M.O., Kirkpatrick, J.P., Patel, M.P., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D.M., and Peters, K.B.: The role of chemotherapy in the treatment of central neurocytoma. CNS Oncol. Published online ahead of print November 5, 2019.
  
  11. Patel MP, Kirkpatrick JP, Johnson MO, Healy P, Herndon JE 2nd, Lipp ES, Miller ES, Desjardins A, Randazzo D, Friedman HS, Ashley DM, Peters KB. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. J Neurooncol. 2020 Apr;147(2):477-483. doi: 10.1007/s11060-020-03446-3. Epub 2020 Mar 5. PMID: 32140975.
  
  12. Gromeier M, Brown MC, Zhang G, Lin X, Wei Z, Beaubier N, Yan H, Desjardins A, Herndon JE II, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Lipp ES, Nair SK, Khasraw M, Peters KB, Randazzo D, Sampson JH, McLendon RE, Bigner DD, and Ashley DM: Very low mutation burden is a feature of inflamed recurrent glioblastomas responsibe to cancer immunotherapy. Nat. Commun. 2021 Jan 13;12(1):352. doi: 10.1038/s41467-020-20469-6. PMID: 33441554.
  
  13. Randazzo DM, McSherry F, Herndon JE II, Affronti ML, Lipp ES, Miller ES, Woodring S, Healy P, Jackman J, Crouch B, Desjardins A, Ashley DM, Friedman HS, Peters KB: Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. Neuro-Onc. Prac. Published online ahead of print Feb 17, 2021.
  
  14. Lee JW, Kirkpatrick JP, McSherry F, Herndon JE II, Lipp ES, Desjardins A, Randazzo DM, Friedman HS, Ashley DM, Peters KB, Johnson MO: Adjuvant radiation in older patients with glioblastoma: a retrospective single institution analysis. Front. Oncol. 2021 Feb 25:11:631618. doi: 10.3389/fonc.2021.631618. eCollection 2021. PMID: 33732649.
  
  07/2013-06/2014
  
  1 year
  
  Assistant Professor of Neurology and Neurosurgery, Duke University, Durham, NC
  
  Passed on 2/20/2021
  
  Kristin Schroeder, MD, MPH
  
  Pediatric Hematology/Oncology
  
  1. Thompson, E., Landi, D., Lipp, E., Balajonda, B., Herndon, J. II, Buckley, E., Flahiff, C., Jaggers, D., Schroeder, K., Randazzo, D., Desjardins, A., Johnson, M., Peters, K., Khasraw, M., Malinzak, M., Mitchell, D., Ashley, D., and Sampson, J.: Peptide vaccine directed to CMV PP65 for treatment of recurrent malignant glioma and medulloblastoma in children and young adults: preliminary results of a phase I trial. Abstract CTIM-21. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii37, 2020.
  
  07/2013-06/2014
  
  1 year
  
  Assistant Professor of Pediatrics
  
  Duke University Medical Center
  
  Durham, NC
  
  Ashley Ghiaseddin, MD
  
  Adult Neurology
  
  1. Ghiaseddin, A., Dunn-Pirio, A., Peters, K., Vlahovic, G., Herndon, J. II, Threatt, S., Sampson, J., Friedman, A., Friedman, H., and Friedman, A.: Phase II trial of bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression. Abstract AT-22. 2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL. Neuro-Oncol. 16, Suppl. 5: v13, 2014.
  
  2. Ghiaseddin, A., Reardon, D.R., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E., McSherry, F., Desjardins, A., Randazzo, D.A., Vlahovic, G., Friedman, H.S., and Peters, K.B.: Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. Abstract 2034. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.
  
  3. Vlahovic, G., Archer, G., Reap, E., Ghiaseddin, A., Desjardins, A., Peters, K., Randazzo, D., Healy, P., Herndon, J.E. II, Friedman, A., Friedman, H., Bigner, D., and Sampson, J.: Combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM). Abstract IMCT-19. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v111, 2015.
  
  4. Ghiaseddin, A., West, M., Hornsby, W., Freeman, M., Lipp, E., McSherry, F., Herndon, J.E. II, Desjardins, A., Friedman, H., Jones, L., Peters, K.: Prospective evaluation of cardiopulmonary fitness in newly diagnosed glioblastoma patients receiving an anti-angiogenic regimen. Abstract QOL-19. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v192, 2015.
  
  2. Ghiaseddin, A. and Peters, K.B.: Use of bevacizumab in recurrent glioblastoma. CNS Oncol. 4(3): 157-169, 2015.
  
  3. Ghiaseddin, A., Reardon, D., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E. II, McSherry, F., Desjardins, A., Randazzo, D., Friedman, H.S., and Peters, K.B.: Phase II study of bevacizumab and vorinostat for patients with recurrent World Health Organization Grade 4 malignant glioma. Oncologist, 23:157-e21, 2018.
  
  07/2014-06/2015
  
  1 year
  
  Clinical Associate Professor
  
  University of Florida College of Medicine
  
  Gainesville, FL
  
  Tammy Hennika, MD
  
  Pediatric Neurology
  
  07/2014-06/2015
  
  1 year
  
  Clinical Assistant Professor of Pediatrics (Courtesy)
  
  Weill Cornell Medicine
  
  New York, NY
  
  Simon Khagi, MD
  
  Medical Oncology
  
  1. Khagi, S., and Peters, K.B.: Antiangiogenic virotherapy: VB-111 targeting glioma. Ex. Opin. Orphan Drugs. 4:1099-1103, 2016.
  
  07/2015-06/2016
  
  1 year
  
  Medical Director of NCCC Sites, Dartmouth Cancer Center, Dartmouth University, NH
  
  Anastasie Dunn-Pirio, MD
  
  Adult Neurology
  
  1. Ghiaseddin, A., Dunn-Pirio, A., Peters, K., Vlahovic, G., Herndon, J. II, Threatt, S., Sampson, J., Friedman, A., Friedman, H., and Friedman, A.: Phase II trial of bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression. Abstract AT-22. 2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL. Neuro-Oncol. 16, Suppl. 5: v13, 2014.
  
  2. Weant, M., Dunn-Pirio, A., Peters, K., Vlahovic, G., Randazzo, D., Herndon, J.E. II, Healy, P., Threatt, S., Sampson, J., Friedman, A., Friedman, H., Desjardins, A.: Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. Abstract ATCT-13. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX. Neuro-Oncology 17(Suppl 5):v4, 2015.
  
  3. Dunn-Pirio, A., Woodring, S., Panta, S., Lipp, E.S., Healy, P., Herndon, J.E. II, Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: Perampanel for treatment of refractory Seizures in patients with gliomas. Abstract PALL-02. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi168, 2017.
  
  4. Johnson, M.O., Kirkpatrick, J.P., Weant, M.P., Dunn-Pirio, A., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: A retrospective, single institution study of central neurocytoma (2004-2016): survival, treatment, and supportive care. Abstract RARE-25. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi215, 2017.
  
  5. Weant, M.P., Kirkpatrick, J., Johnson, M., Dunn-Pirio, A., Healy, P., Herndon, J.E. II, Lipp, E.S., Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma. Abstract RARE-36. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi217, 2017.
  
  1. Dunn-Pirio, A. and Peters, K.B.: Weber’s syndrome due to low-grade astrocytoma. Open J Clin Med Case Rep 1(1): 1005, 2015.
  
  2. Dunn-Pirio, A., Billakota, S., and Peters, K.B.: Postictal magnetic resonance imaging changes masquerading as brain tumor progression: a case report. Case Rep. Oncol. 9:358-362, 2016.
  
  3. Dunn-Pirio, A.M., Howell, E., McLendon, R.E., and Peters, K.B.: Single-agent carboplatin for a rare case of pilomyxoid astrocytoma of the spinal cord in an adult with neurofibromatosis type 1. Case Rep. Oncol. 9:568-573, 2016.
  
  4. Dunn-Pirio, A., Woodring, S., Lipp, E., Herndon, J.E. II, Healy, P., Weant, M., Randazzo, D., Desjardins, A., Friedman, H.S., and Peters, K.B.: Adjunctive perampanel for refractory glioma-associated epilepsy. Epilepsy Behav. Case Rep. 10:114-117, 2018.
  
  08/2015-08/2017
  
  2 years
  
  Assistant Professor, Department of Neurology
  
  UC San Diego Health
  
  San Diego, CA
  
  Margaret Johnson, MD
  
  Adult Neurology
  1. Peters, K.B., Kirkpatrick J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Lipp, E., Boyd, K., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Crapo, J.: First in human clinical trial of metalloporphyrin dual radioprotectant and radiosensitizer, BMX-001, in newly diagnosed high-grade glioma undergoing concurrent chemoradidation. Poster 2239. 2019 ASTRO Annual Meeting, September 15-18, 2019, Chicago, IL.
  2. Peters, K., Congdon, K., Archer, G., Woodring, S., Jaggers, D., Lipp, E., Healy, P., Herndon, J., Soher, B., Vlahovic, G., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Friedman, A., Ashley, D., Yan, H., and Sampson, J.: Safety of tumor-specific peptide vaccine targeting isocitrate dehydrogenase 1 mutation in recurrent resectable low grade glioma patients. Abstract ATIM-31. Neuro-Oncology 21(Suppl 6):vi8, 2019.
  3. Peters, K., Lipp, E., Broadwater, G., Herndon J. II, Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Affronti, M.: Clinical characteristics of low grade glioma patients with non-canonical IDH1 and IDH2 mutations. Abstract NCOG-38. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii137, 2020.
  4. Weant, E., Woodring, S., Randazzo, D.M., Friedman, H.F., Desjardins, A., Vlahovic, G., Healy, P., Herndon, J.E. II , McSherry, F., Lipp, E.,Miller, E., Cone, C., Kim, J.Y., Southerland, C., Brown, C., Carter, M., Johnson, M.P., Peters, K.B, and Affronti, M.L.,: Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. Abstract MASCC-EP178. 2017 MASCC Annual Meeting, June 22-24, 2017, Washington DC. Supp. Care Cancer 25, Suppl. 2: S266, 2017.
  5. Desjardins, A., Randazzo, D., Peters, K.B., Johnson, M.O., Massey, W., Herndon, J.E. II, McSherry, F., Lipp, E.S., Nadler, P., Horak, I.D., Friedman, H.S.: Phase 2 Study of SYM004 for Adult Patients with Recurrent Glioblastoma (GBM). Abstract ACTR-64. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi303, 2017.
  6. Johnson, M.O., Kirkpatrick, J.P., Weant, M.P., Dunn-Pirio, A., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: A retrospective, single institution study of central neurocytoma (2004-2016): survival, treatment, and supportive care. Abstract RARE-25. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi215, 2017.
  7. Weant, M.P., Kirkpatrick, J., Johnson, M., Dunn-Pirio, A., Healy, P., Herndon, J.E. II, Lipp, E.S., Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma. Abstract RARE-36. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA. Neuro-Oncology 19(Suppl 6):vi217, 2017.
  8. Vaslow, Z., Peters, K., Kirkpatrick, J., McSherry, F., Herndon, J. II, Lipp, E., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., and Friedman, H.S.: Long-term outcomes of adult patients with ependymoma. Abstract 150. 2018 70^th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.
  9. Inamullah, O., Kirkpatrick, J., Healy, P., Lipp, E., Johnson, M., Ashley, D., Randazzo, D., Friedman, H. and Peters, K.: Adult pilocytic astrocytoma: clinical management and prognostic factors. Abstract 158. 2018 70^th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.
  10. Peters, K.B., Kirkpatrick, J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Panta, S., Lipp, E., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D. and Crapo, J.: Phase I dose escalation trial of the safety of BMX-001 concurrent with radiation therapy and temozolomide in newly diagnosed patients with high-grade glioma. Abstract ACTR-28. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi17, 2018.
  11. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Thomas, L., Threatt, S., Bullock, C., Herndon, J., Boulton, S., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.: Dose escalation trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract ATIM-36. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi9, 2018.
  12. Johnson, M., Kirkpatrick, J., Weant, M., Vaslow, Z., Lipp, E., Herndon, J., McSherry, F., Desjardins, A., Randazzo, D., Friedman, H., Ashley, D., and Peters, K.: Treatment patterns, outcomes and prognostic indicators in elderly patients with glioblastoma: a retrospective single institution analysis. Abstract HOUT-19. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi117, 2018.
  13. Randazzo, D., Kirkpatrick, J., McSherry, F., Herndon, J., Affronti, M., Johnson, M., Vaslow, Z., Lipp, E., Desjardins, A., Friedman, H., and Peters, K.: Psychosocial distress in patients with recurrent meningiomas. Abstract QOLP-13. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi217, 2018.
  14. Vaslow, Z., Kirkpatrick, J., Affronti, M., Healy, P., Herndon, J., Lipp, E., Thomas, L., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Peters, K.: Clinical and histopathological characteristics of young adults with glioblastoma at diagnosis. Abstract RARE-16. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi239, 2018.
  15. Kang, J., Swisher, C., Kirkpatrick, J., Herndon, J. II, Lipp, E., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., and Peters, K.: Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study. 2019 AAN Annual Meeting, May 4-10, 2019, Philadelphia, PA.
  16. Desjardins, A., Gromeier, M., Herndon, J.E. II, Randazzo, D., Threatt, S., Lipp, E.S., Miller, E.S., Jackman, J., Bolognesi, D.P., Friedman, A.H., Friedman, H.S., McSherry, F., Peters, K.B., Johnson, M.O., Sampson, J.H., Ashley, D.M., and Bigner, D.D.: Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): experience with retreatment of survivors from the phase I trial. Abstract 2060. 2019 ASCO Annual Meeting, May 31 – June 4, 2019, Chicago, IL. J Clin Oncol 37(15s):101s, 2019.
  17. Lee, J.W., Johnson, M.O., Kirkpatrick, J.P., McSherry, F., Herndon, J., Lipp, E., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D., Peters, K.B.: Outcomes following adjuvant radiation therapy in elderly patients with glioblastoma: a retrospective single institution analysis. 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, McCormick Place West, Chicago, IL, September 15 – 18, 2019.
  18. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Threatt, S., Bullock, C., Jackman, J., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.: Dose finding and dose expansion trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract ATIM-24. Neuro-Oncology 21(Suppl 6):vi6, 2019.
  19. Barbour, A., Healy, P., Lipp, E., Herndon, J., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., Kirkpatrick, J., and Peters, K.: Characteristics of short-term survival in patients with glioblastoma: a retrospective analysis. Abstract HOUT-21. Neuro-Oncology 21(Suppl 6):vi116, 2019.
  20. Johnson, M., Ramirez, L., Herndon, J., Massey, W., Lipp, E., Affronti, M., Kim, J.-Y., Friedman, H., Desjardins, A., Randazzo, D., Ashley, D., Casarette, D., and Peters, K.: A time-based model of early palliative care intervention in patients with newly diagnosed glioblastoma, a single institution feasibility study. Abstract QOLP-18. Neuro-Oncology 21(Suppl 6):vi201, 2019.
  21. Randazzo, D., Jackman, J., Herndon, J., Affronti, M., Lipp, E., Cort, N., Desjardins, A., Johnson, A., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.: Mindfulness meditation practice in malignant glioma patients throughout concomitant radiation and temozolomide: a feasibility study. Abstract QOLP-29. Neuro-Oncology 21(Suppl 6):vi204, 2019.
  22. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K.B., Johnson, M.O., Threatt, S., Bullock, C.A., Herndon, J.E. II, Healy, P., Lipp, E.S., Sampson, J.H., Friedman, A.H., Friedman, H.S., Ashley, D.M., and Bigner, D.D.: Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract 2566. 2020 ASCO Virtual Annual Meeting, May 29 – 31, 2020. J Clin Oncol 38(suppl), 2020.
  23. Thompson, E., Landi, D., Lipp, E., Balajonda, B., Herndon, J. II, Buckley, E., Flahiff, C., Jaggers, D., Schroeder, K., Randazzo, D., Desjardins, A., Johnson, M., Peters, K., Khasraw, M., Malinzak, M., Mitchell, D., Ashley, D., and Sampson, J.: Peptide vaccine directed to CMV PP65 for treatment of recurrent malignant glioma and medulloblastoma in children and young adults: preliminary results of a phase I trial. Abstract CTIM-21. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii37, 2020.
  24. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Landi, D., Khasraw, M., Threatt, S., Bullock, C., Herndon, J. II, Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.: A phase I trial of D2C7-IT in combination with atezolizumab in recurrent WHO grade IV malignant glioma (MG). Abstract CTIM-23. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii38, 2020.
  25. Johnson, M., Herndon, J. II, Lipp, E., Affronti, M., Desjardins, A., Bhattacharya, M., Friedman, H., Ashley, D., Peters, K., and Randazzo, D.: Patterns of distress in older patients with glioblastoma: a follow-up to a single institution cross-sectional study of distress in primary brain tumor patients. Abstract NCOG-23. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii134, 2020.
  26. Patel, M., Peters, K., Lipp, E., Low, J., Herndon, J. II, Broadwater, G., Johnson, M., Randazzo, D., Kim, J-Y., and Affronti, M.: Olanzapine for refractory chemotherapy-induced nausea and vomiting in malignant glioma patients. Abstract QOLP-05. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii175, 2020.
  27. Randazzo, D., Buckley, E., Herndon, J. II, Cort, N., Affronti, M., Lipp, E., Desjardins, A., Johnson, M., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.: A feasibility study utilizing mindfulness meditation during concomitant chemoradiation in malignant glioma patients: health-related quality of life (HRQOL) results. Abstract QOLP-20. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii179, 2020.
  28. Peters, K., Randazzo, D., Johnson, M., Kim, J-Y., Patel, M., and Affronti, M.: Engaging patients and caregivers to improve the importance and quality of supportive care research in neuro-oncology. Abstract QOLP-24. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii180, 2020.
  1. Johnson, M.O., Kirkpatrick, J.P., Patel, M.P., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D.M., and Peters, K.B.: The role of chemotherapy in the treatment of central neurocytoma. CNS Oncol. Published online ahead of print November 5, 2019.
  
  2. Patel MP, Kirkpatrick JP, Johnson MO, Healy P, Herndon JE 2nd, Lipp ES, Miller ES, Desjardins A, Randazzo D, Friedman HS, Ashley DM, Peters KB. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. J Neurooncol. 2020 Apr;147(2):477-483. doi: 10.1007/s11060-020-03446-3. Epub 2020 Mar 5. PMID: 32140975.
  
  3. Lee JW, Kirkpatrick JP, McSherry F, Herndon JE II, Lipp ES, Desjardins A, Randazzo DM, Friedman HS, Ashley DM, Peters KB, Johnson MO: Adjuvant radiation in older patients with glioblastoma: a retrospective single institution analysis. Front. Oncol. 2021 Feb 25:11:631618. doi: 10.3389/fonc.2021.631618. eCollection 2021. PMID: 33732649.
  
  10/2016-9/2017
  
  1 year as fellow
  
  Assistant Professor
  
  Duke University Medical Center
  
  Durham, NC
  
  Zachary Vaslow, MD
  
  Adult Neurology
  
  1. Vaslow, Z., Peters, K., Kirkpatrick, J., McSherry, F., Herndon, J. II, Lipp, E., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., and Friedman, H.S.: Long-term outcomes of adult patients with ependymoma. Abstract 150. 2018 70^th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.
  
  2. Johnson, M., Kirkpatrick, J., Weant, M., Vaslow, Z., Lipp, E., Herndon, J., McSherry, F., Desjardins, A., Randazzo, D., Friedman, H., Ashley, D., and Peters, K.: Treatment patterns, outcomes and prognostic indicators in elderly patients with glioblastoma: a retrospective single institution analysis. Abstract HOUT-19. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi117, 2018.
  
  3. Randazzo, D., Kirkpatrick, J., McSherry, F., Herndon, J., Affronti, M., Johnson, M., Vaslow, Z., Lipp, E., Desjardins, A., Friedman, H., and Peters, K.: Psychosocial distress in patients with recurrent meningiomas. Abstract QOLP-13. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi217, 2018.
  
  4. Vaslow, Z., Kirkpatrick, J., Affronti, M., Healy, P., Herndon, J., Lipp, E., Thomas, L., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Peters, K.: Clinical and histopathological characteristics of young adults with glioblastoma at diagnosis. Abstract RARE-16. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi239, 2018.
  
  1. Vaslow, Z., and Peters, K.B.: Low-grade gliomas. MedLink Neurol., accepted for publication July 2020.
  
  07/2017-06/2018
  
  1 year
  
  Medical Director of Neuro-Oncology, Cone Health
  
  Greensboro, NC
  
  Justin Low, MD PhD
  
  Adult Neurology
  1. Low, J., Kirkpatrick, J., and Peters, K.: Pineal parenchymal tumors of intermediate differentiation treated with ventricular radiation and temozolomide. 2019 AAN Annual Meeting, May 4-10, 2019, Philadelphia, PA
  2. Patel, M., Peters, K., Lipp, E., Low, J., Herndon, J. II, Broadwater, G., Johnson, M., Randazzo, D., Kim, J-Y., and Affronti, M.: Olanzapine for refractory chemotherapy-induced nausea and vomiting in malignant glioma patients. Abstract QOLP-05. 2020 SNO Virtual Meeting, November 19-21, 2020. Neuro-Oncology 22(Suppl 2):ii175, 2020.
  1. Low, J.T., and Peters, K.B.: Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. CNS Oncol. Published online ahead of print March 6, 2020.
  
  2. Low JT, Wang S-H, Peters KB: Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman. CNS Oncol. Published online ahead of print April 2021.
  
  3. Low JT, Kirkpatrick JP, Peters KB. Pineal Parenchymal Tumors of Intermediate Differentiation Treated With Ventricular Radiation and Temozolomide. Adv Radiat Oncol. 2021 Sep 29;7(1):100814. doi: 10.1016/j.adro.2021.100814. PMID: 34746517; PMCID: PMC8554459.
  
  07/2018-06/2020
  
  Assistant Professor
  
  Duke University Medical Center
  
  Durham, NC
  
  Kristen Batich, MD PhD
  
  Medical Oncology
  
  1.Batich, K.A., Riedel, RF., Kirkpatrick, J.P., Tong, B.C., Eward, W.C., Tan, C.L., Pittman, P.D., McLendon, R.E., and Peters, K.B.: Recurrent extradural myxopapillary ependymoma with oligometastatic spread. Front. Oncol. Published online ahead of print November 28, 2019.
  
  2.Vlahovic, G., Archer, G., Lally-Goss, D., Reap, E., Batich, K., Desjardins, A., Peters, K., Ranjan, T., Healy, P., Herndon, J. II, Friedman, A., Friedman, H., Bigner, D., and Sampson, J.: Pilot study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM). Abstract IT-34. 2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL. Neuro-Oncol. 16, Suppl. 5: v117, 2014.
  
  3.Batich, K., Ashley, D., Archer, G., Sanchez-Perez, L., Norberg, P., Congdon, K., Herndon, J., McSherry, F., Gemberling, S., Hesler, R., Jaggers, D., Van, R., Parker, J., Peters, K., Desjardins, A., Friedman, H., and Sampson, J.: Enhancing vaccine responses with dose-intensified temozolomide in glioblastoma: initiation of the I-ATTAC trial. Abstract RBTT-02. 2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA. Neuro-Oncology 20(Suppl 6):vi234, 2018.
  
  4.Batich, K., Wang, S-H.J., Salacz, M., and Peters, K.: Synchronous diagnosis of multicentric glioma with distinct molecular profiles. 2021 AAN Virtual Annual Meeting, April 17-22, 2021.
  
  5.Batich, K., Mitchell, D., Healy, P., Herndon, J., Broadwater, G., Michael, G., Huang, M-N., Hotchkiss, K., Sanchez-Perez, L., Nair, S., Congdon, K., Norberg, P., Weinhold, K., Archer, G., Reap, E., Xie, W., Shipes, S., Albrecht, E., Peters, K., Randazzo, D., Johnson, M., Landi, D., Desjardins, A., Friedman, H., Vlahovic, G., Reardon, D., Vredenburgh, J., Bigner, D., Khasraw, M., McLendon, R., Thompson, E., Cook, S., Fecci, P., Codd, P., Floyd, S., Reitman, Z., Kirkpatrick, J., Friedman, A., Ashley, D.M., and Sampson, J.: Reproducibility of clinical trials using CMV-targeted dendritic cell vaccines in patients with glioblastoma. Abstract CTIM-10. 2021 SNO Annual Meeting, November 18-21, 2021. Neuro-Oncology 23(Suppl 6):vi51, 2021.
  
  1.Batich KA, Riedel RF, Kirkpatrick JP, Tong BC, Eward WC, Tan CL, Pittman PD, McLendon RE, Peters KB. Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. Front Oncol. 2019 Nov 28;9:1322. doi: 10.3389/fonc.2019.01322. PMID: 31850213; PMCID: PMC6892774.
  
  2. Vaios EJ, Batich KA, Buckley AF, Dunn-Pirio A, Patel MP, Kirkpatrick JP, Goudar R, Peters KB. Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma. Oncotarget. 2022 Mar 29;13:576-582. doi: 10.18632/oncotarget.28222. PMID: 35359747; PMCID: PMC8963718.
  
  07/2020-Present
  
  Emily Hanzlik, MD
  
  Pediatric Neurology
  1. Hanzlik E, Archambault B, Dairi M, Schroeder K, Patel M, Lipp ES, Boucree S, Peters K, Ashley D, Landi D. LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS. Neuro Oncol. 2021 Jun 1;23(Suppl 1):i32–3. doi: 10.1093/neuonc/noab090.132. PMCID: PMC8168132.
  
  07/2020-06/2022
  
  St. Jude’s Hospital Memphis, TN-Faculty
  
  Madison Shoaf, MD
  
  Adult Neurology
  
  1. Shoaf, M., and Peters, K.: High grade glioma of the spinal cord: a cases series of rare malignancy. 2021 AAN Virtual Annual Meeting, April 17-22, 2021.
  
  1.Shoaf M and Peters, KB. Clinical trial of oncolytic viruses in glioblastoma. Advances in Oncology. 2022 May. 2, 1: 139-158. doi.org/10.1016/j.yao.2022.02.004
  
  07/2020-06/2022
  
  Emory University, Atlanta, GA-Faculty
  
  Katherine Ryan, DO
  
  Pediatric Hematology/ Oncology
  
  07/2021-Present
  
  Avani Mangoli, DO
  
  Pediatric Hematology/ Oncology
  
  07/2022-Present
  
  Kaleigh Fetcko-Fayad, MD
  
  Adult Neurology
  
  07/2022-Present
Teaching Activities
- Program Director, Neuro-oncology Fellowship
  Director of Neuro-oncology Rotation for Neurology and Neurosurgery Residents
  Mentor-Leader, Longitudinal Integrated Clerkship for Duke University School of Medicine
Scholarly, Clinical, & Service Activities
Presentations & Appearances
Outreach & Engaged Scholarship
Service to the Profession
Service to Duke
Academic & Administrative Activities
- Director of Supportive Care, The Preston Robert Tisch Brain Tumor Center at Duke, 2019-present
  
  Program Director, Neuro-Oncology Fellowship, Department of Surgery, Duke University School of Medicine, 2012-present
  
  Creator and Director of CME Course Tumor Board for Neuro-Oncology, Duke University School of Medicine, 2011-2022
  
  Creator and Director of Integrative Neuro-Oncology Conference, 2021-Present
  
  Vice-Chair of Education, Department of Neurology, Duke University, School of Medicine, 2022-Present
Clinical Activities
- I, with an amazing team of nursing and advanced practice providers, actively sees and cares for patients with primary brain tumors.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Medical Licensure

Previous Appointments & Affiliations

Leadership & Clinical Positions at Duke

In the News

Awards & Honors

Subject Headings

Global Scholarship

Expertise

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Journal Issues

Conference Papers

Recent Courses

Advising & Mentoring

Teaching Activities

Presentations & Appearances

Outreach & Engaged Scholarship

Service to the Profession

Service to Duke

Academic & Administrative Activities

Clinical Activities